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Annually over 50,000 patients who are 65 years and older initiate hemodialysis in the 
United Studies. Choosing a vascular access for older dialysis recipients is challenging. Although 
clinical guidelines recommend arteriovenous fistula as the optimal type of vascular access, older 
hemodialysis patients have significantly worse fistula outcomes. For those whose created fistulas 
are not usable in a timely matter, advantages of fistula attempts are greatly compromised. Few 
studies have tracked fistula development and maintenance as an integrated care process in older 
hemodialysis patients. Evidence on the association of age and fistula outcomes is scarce in the 
literature. There is also a call to identify older patients who are more likely to benefit from a 
fistula placement.  
The first contribution of this dissertation is the description of arteriovenous fistula 
development as a process of care from the initial step of fistula placement to achieving 
continuous fistula patency. We examine the proportion, timing, and geographic variability of 
fistula construction and outcomes among older hemodialysis recipients and find only a small 
proportion of them have completed the sequential stages of fistula care in the United States. 
There is a need to address disparities in fistula care continuum to improve fistula outcomes. 
The second contribution of this dissertation is the precisely estimation of the effect of age 
on arteriovenous fistula construction and outcomes. We find increasing age is significantly 
associated with lower probability of fistula placement and maturation but not fistula primary and 
secondary patency loss. We conclude the likelihood of fistula maturation should be the most 
important consideration for vascular access planning in older dialysis recipients and fistula might 
not the best vascular access option for patients approaching eighty years old.  
iii 
 
The third contribution of this dissertation is the externally validation of the Lok’s risk 
equation for fistula primary failure which has achieved good prediction accuracy previously. We 
show the Lok’s model is invalid to predict fistula primary failure in the U.S. older hemodialysis 
patients. Finally, we use random survival forests to identify important predictors for fistula 
maturation and find patient’s gender might be considered as the most important predictor for 
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Chronic kidney disease (CKD) is a condition in which the kidney is damaged to an extent 
such that it no longer has a capability to filter blood. The last stage (stage 5) of CKD is called 
End Stage Renal Disease (ESRD). It is a permanent state of advanced kidney failure that requires 
kidney replacement therapy (KRT, dialysis or kidney transplantation) to sustain life. Diabetes, 
hypertension, cardiovascular disease, and genetic defect are common risk factors for CKD.  CKD 
and ESRD can lead to premature death and decreased health-related quality of life for those 
affected. In addition, approximately a quarter of Medicare budget was spent on treating CKD and 
ESRD patients.
1
 The Healthy People 2020 identified CKD as one of nationwide health 
improvement priorities.
2
  Care of CKD and ESRD has significant public health and clinical 
implications. It represents a great opportunity to improve patient outcomes and reduce healthcare 
costs. It was estimated that annually, more than 12,000 life years could be saved if a current 
practice meets the targets in clinical guidelines in six major areas of  ESRD care, including 
dialysis dose, phosphate control, anemia treatment, serum albumin correction, interdialytic 







PART ONE: END STATE RENAL DISEASE AND HEMODIALYSIS 
 
Incidence and Prevalence of End Stage Renal Disease and Hemodialysis  
The US ESRD incidence rate has increased substantially since the 1990s, before leveling 
in the 2000s.
4
 In 2013, however, the rate began to rise again. In 2015, there were 124,114 newly 
reported cases of ESRD and the crude incidence rate was 378 per million population (PMP).
4
 
With an escalating incidence rate and aging of the U.S. population, the ESRD prevalence has 
grown continuously from the 1990s.
4
  At the end of 2015, the ESRD population had increased to 
703,243 patients. The crude prevalence rate had reached 2,128 PMP.
4
 
Of all U.S. ESRD patients, over 440,000 (63%) are maintained on hemodialysis.
4
 Only 
30% live with a functioning transplanted kidney, and 7% are treated by peritoneal dialysis.
4 
Among hemodialysis patients, an overwhelming majority of them (98%, over 430,000 patients) 
use in-center hemodialysis, while only 2% dialyze at home.
4 
The distribution of incident 
treatment modalities follows the same pattern. In 2015, for example, a dominant portion of the 
incident ESRD patients (87%) initiated their KRT with hemodialysis. Only 2.5% of them 




Mortality and Morbidity of End Stage Renal Disease and Hemodialysis 
The past decade has witnessed a significant decline in ESRD mortality and 
hospitalization rate. The adjusted mortality rate of the ESRD population after controlling for the 
population characteristics decreased by 28% from 189 per 1,000 person-years in 2001 to 136 in 
2015.
4
  In 2015, the adjusted mortality for hemodialysis patients, peritoneal patients, and 
transplant patients were 169, 159, and 29 per 1,000 person-years, respectively.
4
 The adjusted rate 
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of hospital admission for hemodialysis and peritoneal dialysis patients has declined 19%, from 
2.1 per patient year in 2006 to 1.7 in 2015.
4
 In 2015, hemodialysis patient hospitalizations due to 




Medicare Expenditures on End Stage Renal Disease and Hemodialysis 
Since the October of 1972, Medicare has extended its coverage to all ESRD patients and 
created the first universal disease-based health care system in the U.S..
5
 Most patients with 
ESRD are eligible for Medicare coverage 90 days after initiation of their kidney replacement 
therapy. ESRD care has poses a significant national health care burden. Although comprising 
less than 1% of the Medicare population, the ESRD population consumed 7% ($34 
billion) of the total Medicare expenditures in 2015.
4
 When adding an extra $64 billion of CKD 
costs, total Medicare spending on both CKD and ESRD was over $98 billion.
4
 In 2015, the 
Medicare spending for hemodialysis population was $26.7 billion in total and $88,195 per 
patient per year (PPPY).
4
 While the PPPY for hemodialysis patients remains stable, the escalated 






PART TWO: VASCULAR ACCESS 
 
Types of Vascular Access for Hemodialysis 
A well-functioning and reliable vascular access is essential for efficient hemodialysis. 
The three basic access types used by most hemodialysis patients are arteriovenous fistula (AVF), 
arteriovenous graft (AVG), and central venous catheter (CVC) (Figure 1). An AVF is a naïve 
connection of an artery to a vein created by a vascular surgeon on patient’s forearm 
(radiocephalic) or upper arm (brachiocephalic and brachiobasilic). After placement, a typical 
AVF needs at least 2 to 3 months to achieve vein enlargement and an increase in tissue mass to 
be usable for dialysis. An AVG is similar to an AVF; it uses a looped, plastic tube as a 
connection. A patient can usually use an AVG 2 to 3 weeks after placement. A CVC is a tube 
inserted into a vein in patient’s neck, chest, or leg, usually for short-term use. Observational 
studies have demonstrated that AVFs, once functional, exhibit greater longevity, are less prone to 
infection, and are also associated with reduced mortality and lower cost, compared with AVGs 
and CVCs.
6,7
 CVC, on the contrary, is deemed the most inferior of all three access types and 
should only be used as a temporary access for hemodialysis. It is related to substantially elevated 
rates of infection
8,9
 and increased all-cause mortality.
10,11
 However, it might be the only choice 
for patients with a limited life expectancy, or when the surgical creation of an AVF is dangerous 
because of the risk of cardiac failure.
12
 AVGs tend to require more interventions and are more 
likely to fail after successful use compared to AVFs, but they have a higher initial rate of 
successful use compared to AVFs and lower infection rates compared to CVCs.
13
 Studies have 
shown when rates of primary failure are considered, AVGs do not differ significantly from AVFs 






“Fistula First” Initiative and Clinical Guidelines for Vascular Access 
In 2003, the Centers for Medicare and Medicaid Service (CMS) launched the National 
Access Improvement Initiative (NVAII), later renamed as the Fistula First Breakthrough 
Initiative (FFBI).
6
 The goal of FFBI is to achieve functional AVF use in greater than 65% of 
hemodialysis patients and to reduce CVC utilization in less than 10% of hemodialysis patients. 
In collaboration with the 18 national ESRD Networks, CMS promulgated the FFBI goal through 
its Clinical Performance Measures (CPMs) and established Quality Improvement and Patient 
safety (QIPS) rules with financial incentives to improve AVF use. Dialysis units that do not 
achieve the AVF target will face reimbursement penalties.
17
 The 2006 National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (NFK/KDOQI) Clinical Practice 
Guidelines for vascular access echoed “Fistula First” with its similar recommendations.
18
  To 
emphasize the importance of CVC avoidance, CMS also updated the FFBI and renamed it 
“Fistula First Catheter Last” (FFCL), highlighting the needs to establish AVF or AVG and 




Prevalence and Incidence of Each Type of Vascular Access  
Arteriovenous Fistula (AVF) 
The FFCL policy has made dramatic progress; it successfully raised prevalent AVF use 
in the U.S. from 24% in 1997
20
 to 63% in 2016.
4
 However, the incident rate of AVF use at the 
initiation of dialysis has not been changed significantly. The proportion of patients using an AVF 
for vascular access at dialysis initiation was 17% in 2015,
4
 compared to a lesser 12.3% in 2005.
21
  
Similarly, the rate of initiating dialysis with either an AVF or a maturing AVF has only increased 
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slightly from 29% to 33% over the same period of time.
4,21
 From a longitudinal prospective, rate 
of AVF utilization in U.S. rises gradually after dialysis. At dialysis initiation, 17% of patients use 
AVF.
4




Arteriovenous Graft (AVG) 





 In the middle of 2016, only 3% of hemodialysis patients used an AVG for dialysis 




Central Venous Catheter (CVC) 
FFCL has effectively reduced prevalent CVC use. From 1997 to 2015, CVC presence in 




 In spite of the reduction in CVC 
use, approximately 80% of patients are still using a CVC to initiate dialysis in 2015, which has 




In summary, the trend of vascular access use in the past decade has reflected a marked 
increase in prevalent AVF and decrease in prevalent CVC use. However, placement and use of 
AVG have been diminished, since there is now a trend of using CVC as a “bridge access” to 





PART THREE: FISTULA CARE 
 
Fistula Care Continuum 
The continuum of AVF care has three distinct processes, with a requirement that each of 
the three must be successfully overcome in order to reach a useable AVF. First, a patient must be 
referred to a vascular surgeon and an AVF must be created.  Second, the AVF must mature 
sufficiently in order to be used repeatedly to deliver dialysis.  Third, once the AVF has matured, 
it needs to remain patent for a prolonged period of time. Suboptimal delivery of any of these 
three processes of care will result in a lower rate of AVF utilization. 
 
AVF Placement  
To obtain a usable AVF at dialysis initiation, an AVF must be placed early to allow 
sufficient time for maturation and revision. The KDOQI guidelines emphasize that patients with 
stage 4 CKD (GFR<30 ml/min/1.73 m
2
) should be consulted with options for KRT and be 
referred to permanent vascular access placement if the patient agrees to proceed with 
hemodialysis. Ideally, such a patient should have an AVF placed 6 months before dialysis to 
avoid CVC use. Nevertheless, this timeline is achieved in only a minority of patients. Merely 30% 
of AVFs placed in U.S. prevalent hemodialysis population are created prior to initiation of 
dialysis.
4
 Of the AVFs created pre-dialysis, nearly half of them (47%) are created at the time 
approaching (within 90 days of) dialysis initiation.
4
 Consequently, over 80% of patients in the 
U.S. initiate dialysis with a CVC, which serves as a “bridge access”, until an AVF or an AVG 






These disappointing statistics of late AVF/AVG placement might be attributed by several 
reasons. Firstly, more than a third of incident ESRD patients in the U.S. received little to no pre-
ESRD nephrology care.
4
 These patients are more likely to have their AVF/AVG placement 
postponed and instead initiate dialysis with a CVC. This is evidenced by the fact that 35% of 
patients who initiated dialysis with a CVC had no pre-ESRD care.
4
 Secondly, the glomerular 
filtration rate (GFR) trajectory is difficult to project and varies with age and comorbid conditions. 
Therefore, it is very challenging to accurately predict the likelihood and timing of dialysis 
initiation. Despite tight nephrology follow-ups, for instance, 20 - 40% of patients with CKD 
experienced sudden GFR drop that led to urgent dialysis initiation.
23
  On the contrary, 18% of 





AVF Primary Failure, Maturation, and Assisted Maturation 
Whereas the definitions of AVF maturation vary greatly in literature, AVF maturation 
generally is judged by whether or not AVF is ready to provide an adequate delivery of blood to 
the dialyzer. It is expected that once an AVF is formed, increase in blood flow will progressively 
dilate blood vessels and thicken vessel walls to an extent as to sustain repeated cannulation for 
dialysis.
25,26
 In 2011, The North American Vascular Access Consortium (NAVAC), a group of 
multidisciplinary experts from the U.S. and Canada, published common standards for 
terminology in the field of vascular access. They defined AVF maturation as that an AVF can be 
used with two-needle cannulation for two-thirds or more of all prescribed dialysis for one 
month.
27
 The National Institute of Health Hemodialysis Maturation (HFM) Study in 2014 
described AVF maturation as “with 2 needles for 75% of dialysis sessions over a continuous 4-
11 
 
week period and either: (1) 4 consecutive sessions during the 4-week period in which 2 needles 
are used and the mean dialysis machine blood pump speed is ≥300 mL/min. or (2) a measured 
single-pool Kt/V≥1.4 or urea reduction ratio >70% during any session in which 2 needles are 
used within the 4-week period”.
28
  In addition to proving adequate delivery of blood, the 
definition of AVF maturation must have a time component since longer follow-ups allow more 
AVF to mature. The HFM study defined AVF maturation within 9 months of AVF creation or 
within 8 weeks of dialysis initiation.
28
  
NAVAC defined AVF primary failure as an AVF immediate fails within 72 hours of 
surgery (immediate failure), or is not suitable for dialysis despite interventions (radiologic or 
surgical) by the three (early suitability failure) to six months (late suitability failure) following its 
creation.
27
 As compared to primary failure, failure-to-mature does not include early technical 
failures such as intraoperative thrombosis. 
A substantial proportion of newly placed AVFs failed to mature and thus required 
additional interventional procedures to promote maturation (“assisted maturation”). As the 
USRDS data report noted, of AVFs placed between June 2014 and May 2015, 36% of failed to 
mature sufficiently for dialysis.
4
 One meta-analysis which included studies published in 2000 or 
later, the AVF primary failure rate was 23%.
29
 In one cohort study of elderly Medicare 
beneficiaries who initiated hemodialysis from 2010 to 2011, 40-63% of placed AVFs underwent 
one or more interventional procedures to assist maturation.
30
 These procedures usually include 
angioplasty or surgical revision of an anastomotic stenosis, ligation or coiling of large accessory 
veins, or superficialization of excessively deep AVFs. Interventional procedures consume 
radiological and surgical resources, and often lead to prolonged period of dialysis dependency on 
CVC, which is associated with substantially elevated rates of infection
8,9




Moreover,  biological changes caused by these procedures may engender certain detrimental 
effects, which leads to suboptimal AVF outcomes. Studies have shown that AVFs which 
experienced pre-maturation intervention have shorter patency and are more likely to require post-
maturation interventions to maintain functionality compared to those that matured without 
assistance.
31
 There have been limited published information on differential impact of 
interventional procedures by type and frequency on AVF patency after maturation. A small study 
of 77 hemodialysis patients who had an AVF placed and received subsequent interventional 
procedures (55 patients received endovascular vs. 16 received surgical revisions) indicated that 
there was no difference in AVF patency when comparing patients who had endovascular verse 





Many measurements of AVF long-term outcomes after maturation are clinically 
meaningful. But the most frequently used in clinical research could be categorized into 
descriptions of access patency (primary, cumulative, or functional) and patency loss. Primary 
patency, also known as unassisted patency, is the time from AVF creation until any intervention 
to maintain or restore blood flow. Loss of primary patency denoted a requirement for any 
intervention after successful use of AVF. Secondary patency, also called assisted or cumulative 
patency, is the time from AVF creation until the AVF can no longer be used for dialysis and the 
associated problem cannot be corrected by any intervention. Functional patency (primary or 
secondary), however, is different from the above two types of patency in that it counts time from 
AVF maturation or successful cannulation instead of AVF creation. For example, AVF primary 
functional patency is defined as the time from AVF maturation until first revisions. In addition, 
13 
 
some studies examine AVF survival after certain procedures promoting maturation. For example, 
postintervention primary patency is the time from the index procedure until the next AVF 
intervention.  
A few studies have examined AVF post-maturation patency. Patency rates can vary 
greatly by patient population, previous access history, follow-up time, and the year of study. For 
example, analysis of a cohort study of 293 patients at Mayo Clinic with an AVF placed found 
that 3-, 6-, 12-, and 18-month primary patency rates were 67%, 50%, 41%, and 30%, and 
secondary patency rates were 92%, 86%, 77%, and 73%, respectively.
33
 One study evaluating 
vascular access outcomes in 9,458 elderly Medicare patients who initiated hemodialysis from 
2010 to 2011 reported that primary and secondary patency rates were 73% and 82%, respectively, 




Costs Associated with Fistula 
Thamer et al. has recently published a paper on Medicare expenditures on AVF.
30
 In their 
paper, they followed three groups of patients that initiated hemodialysis from 2010 to 2011 and 
examined their vascular access-associated costs by AVF outcomes. The first cohort includes 
patients who initiated hemodialysis with a matured AVF; the second, the patients who initiated 
hemodialysis with a maturing AVF; and the third, patients who initiated hemodialysis with a 
CVC. The results of their study showed that PPPY costs 2.5 years after AVF creation were  
$7,871, $13,282, $17,808, and $31,630 respectively, for patients whose AVFs maintained 
primary patency, patients whose AVFs experienced primary patency loss, and secondary patency 
loss in year 1, for AVFs that were not used. They also showed that the annual Medicare 
expenditures on vascular access-related services from 2011 to 2013 sum up to $2.8 billion, which 
14 
 
is ~12% of all ESRD spending.   In addition, the costs of AVF placement and interventions are 
not trivial. It was estimated that the fistula costs per patient per year in the first two and half 
years after AVF placement were $13,282 for patients whose AVFs had primary failure and 
$30,818 for patients whose AVFs were abandoned. 
 
Disparities in Fistula Care 
Significant disparities exist in likelihood of AVF placement, maturation, and patency.  
 
Racial Disparities 
African Americans are less likely to use an AVF. In spite of the overall increase in AVF 
use among U.S. hemodialysis patients, the gains have been less pronounced in blacks than in 
whites. AVF use is lower in blacks than whites in almost all the 18 dialysis networks.
7
 An 
analysis of 1,824 hemodialysis patients enrolled in the Hemodialysis (HEMO) Study between 
1995-99 reported AVF use in 27.7% of blacks vs 45.5% of non-blacks.
35
 Blacks were 36% less 
likely to use an AVF even after controlling for age, gender, obesity, cardiovascular disease, 
income, education, and insurance status. A subsequent analysis of U.S. patients initiating dialysis 
with a CVC in 1999-2003, observed racial disparities in conversion to a permanent access during 
the first 3 months of hemodialysis.
36
 As compared to white males, black females and black males 
were 75% and 35%, respectively, more likely to maintain CVC use. Finally, a national survey for 
2012-14 revealed AVF use in 58% of black hemodialysis patients vs 70% of whites.
22
 The racial 
differences were particularly striking in black women: 75% AVF use in white men, 65% in black 
men, 65% in white women, and 50% in black women. In other words, the absolute rate of AVF 
use was 15% lower in black women than white women. Notably, racial disparities in the 
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frequency of AVF use between blacks and whites begin at dialysis initiation and increase over 
time after initiation of hemodialysis. At dialysis initiation, the proportion of blacks and whites 
using an AVF is 15.4 vs 17.7%, and the disparity increases progressively during the first year on 
dialysis (22.5 vs. 26.2% at 3 months; 40.1 vs. 47.2% at 6 months; 52.8 vs. 61.0% at 9 months; 
and 58.8 vs. 67.8% at 1 year). Thus, the absolute difference in AVF use between blacks and 
whites increases from 2.3% at hemodialysis initiation to 9.0% at 1 year, indicating processes of 
care to achieve an AVF likely differ substantially between the races.
37
   
 
Gender Disparities 
The substantial gender disparity in AVF maturation among hemodialysis patients has 
been observed repeatedly in many studies. For example, an analysis of 1,824 patients enrolled 
from 1995 to 1999 in the HEMO Study reported AVF use in 22.4% of female patients vs. 46.3% 
of males.
35
  Similarly, the USRDS report from 1999 documented a strikingly lower rate of AVF 
use in prevalent female vs. male hemodialysis patients in each of the 18 U.S. dialysis networks, 
with the absolute rate being approximately 20% lower in females.
7
 Though the overall proportion 
of patients dialyzing with an AVF has increased greatly in both genders following the 2003 
Fistula First Initiative,
19
 the gender discrepancy persists. The Dialysis Outcomes Practice 
Patterns Study (DOPPS) of prevalent U.S dialysis patients from 2010 to 2013 reported a lower 
use of AVFs in women than in men for both black patients (50 vs. 65%) and for non-blacks (65 
vs. 75%).
22
  Most recently, the 2017 USRDS report documented AVF use in 55.2 % of female 
patients vs. 68.8% of males, an absolute difference of 13.6%.
38
 The gender gap in AVF use 
persists a full year after dialysis initiation. At 6 months and one year, females had 13.3% and 
14.7% lower proportion of AVF use as compared to males.  
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Whereas the rate of AVF use is distinctly lower in females as compared to male patients, 
studies have yielded conflicting results in regard to the association of gender and AVF post-
maturation outcomes. A meta-analysis of 37 early reports published from 1970 to 2002 
concluded that females have similar AVF primary failure rates, and primary and secondary 
potencies as males.
39
 However, a study of 2,247 dialysis patients with a newly placed AVF from 
the Dialysis Morbidity and Mortality Study (DMMS) from 1997-99 reported that the risk of AVF 
primary failure was 18% greater in females than in males. The rate of AVF secondary failure, 
however, did not differ significantly between females and males.
40
  In particular, a single center 
study observed that females experienced a greater rate of AVF failure than males, despite routine 
preoperative mapping and more frequent interventions in females to promote maturation.
41
 The 
association of female sex and higher rate of AVF primary failure was also confirmed by a multi-
center study of 395 patients with AVF placement from 2004 to 2006.
42
 Similarly, two newer, 
small studies have examined the impact of gender on AVF assisted maturation and outcomes. 
The first study included 173 hemodialysis patients who had a new AVF placed between 2005 
and 2007 and did not experienced an AVF primary failure.
31
  This study showed that female 
gender is associated with higher proportion of interventions before AVF maturation. The second 
study followed 289 patients that initiated hemodialysis with a CVC from 2006 to 2011 and had a 
subsequent AVF placed. 
32
 The evidence displayed that female patients are more likely to require 
interventional procedures to facilitate maturation compared with male patients. However, gender 
is not significantly associated with secondary functional patency.  In both studies, assisted access 
maturation was associated with higher rates of access abandonment and an increased frequency 





As pointed out by multiple studies, older age is an independent risk factor associated with 
a lower rate of AVF maturation and inferior AVF long-term outcomes.
43,44,45 
Nationwide, the rate 
of AVF use is lower among patients aged 75 years or older (59%) as compared to those aged 65 
and younger (65%).
4
 One meta-analysis of AVF outcomes from 10 studies concluded that elderly 
patients aged >50 to >70 had significantly reduced one-year primary and secondary patency and 
maturation rates.
46
 The odds of AVF primary failure in elderly patients aged >50 to >70 were 1.5 
times of those of non-elderly at 12 months and 1.4 times at 24 months. In an economic study 
examining the resources and costs associated with creating and maintaining AVFs, 40-63% of 
functional AVFs placed in the U.S. elderly between 2011 and 2013 required therapeutic 
interventions to facilitate maturation.
30
 A total of 71-86% of these AVFs required post-
maturation interventions to maintain their functionality during the first year after placement. 
AVFs placed in older hemodialysis patients are more likely to take longer time to mature. As 
noted in the 2017 USRDS report, a quarter of AVFs placed in surviving hemodialysis patients 




Comorbid Disease Disparities 
Comorbid conditions can have a major impact on the prevalence of patients dialyzing 
with AVFs. Early studies showed a difference in the prevalence of AVF maturation and AVF 
long-term outcomes between patients with and without diabetes. For example, the Dialysis 
Outcomes and Practice Patterns Study noted that among the 3,882 American and 2,597 European 
prevalent hemodialysis patients from 1996-2000, those without diabetics were 32% more likely 
to use AVF compared to patients without diabetes.
20
 The DMMS study of 2,247 dialysis patients 
with a newly placed AVF from 1997-99 noted that patients with diabetes had 10% increased risk 
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of primary failure, compared to patients without diabetes. 
40
 But diabetes is not associated with 
an increased risk of secondary failure. Changes of practice patterns in recent years have 
gradually closed up the gaps in AVF use among diabetic patients. A single-center analysis of 195 
patients suggested that vascular mapping could greatly improve the rate of AVF placement in 
diabetic patients through careful preoperative vessel imaging and AVF site selection.
47
 In this 
study, there was only a 6% difference in the rate of AVF placement between diabetic and non-
diabetic, and AVF outcomes were similar regardless of the presence of diabetes. A multi-center 
study of 395 patients with AVF placement from 2004 to 2006 suggested that diabetes was 
significantly, but marginally, associated with primary function patency loss.
42
 Another single-
center study of 748 patients also demonstrated that increased use of AVFs and satisfactory AVF 
outcomes in diabetic patients could be achieved by proper preoperative evaluation, exclusive use 
of native vessels and a variable surgical approach.
48
 Most recently, the 2017 USRDS report 
documented comparable rates of AVF use in prevalent and incident hemodialysis patients with 





Practice patterns can have a major impact on the prevalence of patients dialyzing with 
AVFs. The DOPPS study reported that AVF use in 2013 varied greatly across US dialysis 
facilities, ranging from 54% to 84%.
22
 Two early reports found substantial geographic variations 
in the prevalence of AVF use. Higher AVF use was found in the U.S. Northeastern region while 
the South had lower rates of AVF use.
35,49
 In both reports, these geographic differences persisted 
even after the adjustment of multiple demographic factors and co-morbid conditions. Similarly, 
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variations in AVF use were also reflected in more recent national data, that the Northwest region 
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Figure 1. Three type of hemodialysis vascular access: arteriovenous fistula (AVF), arteriovenous 


























Background: Arteriovenous fistula (AVF) development could be viewed as a care process from 
the initial step of AVF placement to achieving the goal of continuous AVF patency. Our study 
aims to evaluate the proportion, timing, and geographic variability of AVF development and 
outcomes in the U.S. older hemodialysis recipients.  
Methods: We assembled a retrospective cohort of incident hemodialysis adults aged 67 years 
and older who initiated dialysis (43,851), had an AVF placed (14,892), or had the placed AVF 
matured (7,528) from the United States Renal Data System. We determined rates of AVF 
placement, maturation, and patency loss in total, by month, and by geographic region and ESRD 
network. The incidence rates of pre- or post-maturation interventions were reported. Logistic 
regression model was used to examine the association of geographic regions with AVF outcomes, 
adjusted by age, gender, race, BMI, functional status, and comorbid score. 
Results: Only 13% of older patients who initiated dialysis with a CVC completed the three 
processes of AVF care and maintained functionality 2 years after AVF maturation. The ranges of 
pre- and post-maturation interventions rates were 0 to 8.4 and 0 to 1.1 per patient per month. The 
median time from dialysis initiation to AVF placement and from placement to maturation was 2 
months (IQR: 1-4) and 5 months (IQR: 4-7). The median AVF primary and secondary functional 
patency was 2 months (IQR: 1-5) and 3 months (IQR: 2-7). There existed moderate geographic 
variations in AVF placement and patency. Geographic difference in AVF maturation was not 
evident. 
Conclusion: A small proportion of older incident hemodialysis patients have AVF placed, 
matured, and remained patent. These findings highlight the critical need for early AVF 




Current clinical guidelines recommend a well-functioning arteriovenous fistula (AVF) as 
the preferred form of vascular access for hemodialysis.
1 
 To achieve a useful and lasting AVF, an 
AVF must be placed, mature sufficiently, and remain patent to deliver dialysis. Ideally, if the 
three processes are completed promptly, patients are able to avoid or reduce use of a central 
venous catheter (CVC) for dialysis, which is associated with increased all-cause mortality.
2,3,4
  
Annually more than 50,000 patients aged 65 and older with the end stage renal disease 
(ESRD) initiate hemodialysis in the United States.
5 Older adults are also the fastest growing 
segment of the prevalent dialysis population due to the escalating rate of ESRD incidence, aging 
of the U.S. population, and prolonged survival on dialysis. Studies show older age is 
significantly associated poor AVF outcomes. Nationwide, the prevalence of AVF use was lower 
in patients over 75 years (61%) as compared to those 65-74 (64%) and 45-64 (67%).
5
  In the 
meta-analysis of AVF outcomes from 10 studies which defined elderly from >50 to >70 years 
old, the rate of AVF maturation failure was significantly higher in elderly compared with that in 
nonelderly.
6
 In addition, AVFs placed in older adults are likely to take longer time to mature. As 
noted in the 2017 USRDS report, the median time from AVF placement to maturation is 116 
days in patients aged 65-74 as compared to 109 days in patients aged 45-64.
5 
 Despite suboptimal 
AVF outcomes in this growing population, few studies have tracked AVF development and 
maintenance as an integrated care process. Our study aims to evaluate AVF care as a continuum 
model as the proportion of individuals, the timing of achievement, and the geographic variability 
at each stage of AVF development and maintenance in the U.S. older hemodialysis recipients. It 





Data Sources and Study Population  
Our primary data source was derived from the 2010-2014 USRDS standard analytic files 
(SAFs).  Figure 1 demonstrated development of our three study cohorts.  Cohort 1, the 
hemodialysis cohort, included 43,851 incident patients aged 67 years and older who initiated 
dialysis through a CVC between 7/1/2010 and 6/30/2012. To ensure that the CVC was the only 
vascular access present at the start of hemodialysis therapy, patients were excluded if they: (1) 
were using an AVF or AVG or had an AVF or AVG placed but were awaiting maturation at 
hemodialysis therapy initiation, as reported in the Medical Evidence Form; (2) underwent AVF 
or AVG surgery in the 2-year pre-ESRD period, as assessed by Current Procedural Terminology-
4 (CPT-4) procedure codes of 36818, 36819, 36820, 36821, and 36825 for AVF and 36800, 
36810, and 36830 for AVG. From the hemodialysis cohort (cohort 1), we further identified two 
subcohorts. Cohort 2, the AVF placed subcohort, included 14,569 patients who had AVF 
placements within 6 months after dialysis initiation. Cohort 3, the AVF matured subcohort, 
included 7,301 patients whose AVFs matured within 6 months after placement.  
 
Variables of Interest  
The primary outcomes of this study were AVF placement (cohort 1), AVF maturation 
(cohort 2), and primary and secondary patency loss (cohort 3). We identified AVF placement by 
using CPT-4 codes as listed above. AVF maturation was ascertained by using the first vascular 
access modifier code ‘V7’ reported from the institutional details claims file or the first AVF used 
with two needles reported from the Crownweb clinical file. Patients were considered to have 
assisted maturation if they underwent an intervention prior to maturation, and to have unassisted 
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maturation if they did not undergo such an intervention. Codes used to identify intervention 
procedures including angioplasty, thrombectomy, revision, ligation, banding, and embolization 
of accessory veins were listed in Table S1. We defined AVF primary patency loss as the first 
revision procedure after maturation. We defined AVF secondary patency loss (abandonment) as 
3 consecutive months of CVC use or a new vascular access placement. Primary and secondary 
functional patency was ascertained as the time from AVF maturation to primary patency loss or 
abandonment, respectively. Cohort 1 was followed for 3 years from dialysis initiation. Cohort 2 
was followed for 2 years from AVF placement. Cohort 3 was followed for 2 years from AVF 
maturation. Patients who died, switched to peritoneal dialysis, or received a kidney transplant 
during the follow-up period were identified by using the USRDS death file, the transplant file 
and dialysis institutional claims file, respectively. 
We extracted patient demographics, residential region (New England, Mid-Atlantic, West, 
Southwest, Midwest, and South), BMI, functional status (amputation, inability to ambulate or 
transfer, needs assistance with daily activities, or institutionalized), lab values (hemoglobin, 
serum albumin, and glomerular filtration rate), primary cause of renal failure, pre-dialysis 
nephrology care, and facility provider ID from the Medical Evidence Form. In addition, 2-year 
pre-ESRD CMS Medicare claims were used to identify major comorbidities conditions. ESRD 
network number, facility’s profit status and hospital association were ascertained from the 
facility file.  
 
Statistical Analysis 
We summarized baseline patient characteristics and facility practice patterns for each 
study cohort. Rates of AVF placement, maturation, and primary and secondary patency loss were 
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determined in total and by month. The incidence rate of pre- or post-maturation interventions 
was calculated as number of interventions divided by time needed to achieve maturation or 
length of secondary functional patency. We also examined distribution of AVF outcomes by 
ESRD network. Logistic regression model was used to examine geographic regions with AVF 
outcomes, adjusted by age, gender, race, BMI, functional status, and comorbid score. Data 




Table 1 lists patient characteristics in three study cohorts. Cohort 1 included 52.4% male, 
75.4% White, 15.8% aged 85 and older, 65.3% diabetic, 74.3% hypertensive and 63.5% with 
coronary artery disease. The two subcohorts, cohort 2 and 3, consisted of slightly higher 
proportions of males (54.5% and 60.1%), lower percentages of Black (18.5% and 16.9%), and 
lower proportions of patients aged 85 and older (13.8% and 13.2%).  Patients in three cohorts 
carried heavy comorbid burdens and had low functional status. In the aspect of care patterns, 
over 80% of patients dialyzed in a for-profit facility and 48-55% had pre-dialysis nephrology 
care.  
Fistula Care Continuum 
Nationally, among 100 older adults who initiated hemodialysis with a CVC, 39 of them 
had an AVF placed within 3 years, 27 of them had their placed AVF matured within 2 years after 





AVF Placement from the Hemodialysis Cohort 
Of 43,851 patients who initiated hemodialysis with a CVC in cohort 1, 39.4% of them 
had an AVF placed within 3 years of dialysis initiation and 40.8% died, received a kidney 
transplant, or transferred to peritoneal dialysis.  The majority of AVFs (83.8%) were placed 
within 6 months after dialysis initiation and 60.5% were placed from the 2nd to 4th month. The 
3
rd
 month after dialysis initiation has the highest placement rate (24.0%). The median time from 
dialysis initiation to AVF placement was 2 months (IQR: 1-4) (Figure 3A). 
 
AVF Maturation from the AVF Placed Cohort 
Among 14,892 patients in cohort 2 who had an AVF placed within 6 months of dialysis 
initiation, 68.9% of them had their AVFs matured and 20.3% died, had a kidney transplant, or 
transfer to peritoneal dialysis without using AVFs. Figure 3B showed distribution of AVF 
maturation in each month after AVF placement. The highest proportion of AVFs matured in the 
4th month after placement (21.1%). Within 6 months of AVF placement, 73.3% of AVFs 
matured. The median time to reach maturation was 5 months (IQR: 4-7) and 25% of patients 
took 7 months or more to use their AVFs (Figure 3B). 
In cohort 2, over half of the matured AVFs (55%) required one or more interventions to 
facility maturation (i.e. assisted maturation).  The distributions of number and incident rate of 
pre-maturation interventions were highly screwed: the number varied from 0 to 42 with the 
median of 1 (IQR: 0-2); the incident rate varied from 0 to 8.4 per patient per month with the 
median of 0.1 (IQR: 0-0.3) (Table 2).  Approximately 1% of the matured AVFs had ≥ 9 




AVF Primary Patency Loss from the AVF Matured Cohort 
Of 7,528 matured AVFs in cohort 3, 75.2% of them experienced primary patency loss. 
Approximately 10.9% continued using AVF without any revision and 13.9% died, had a kidney 
transplant, or transferred to peritoneal dialysis within 2 years after maturation. A majority of 
primary patency loss (80.4%) occurred in the first 6 months. It was most likely to occur in the 
first month (32.6%).  The median primary functional patency was 2 months (IQR: 1-5) (Figure 
3C). 
 
AVF Abandonment from the AVF Matured Cohort 
A total of 25.2% of matured AVFs were abandoned within 2 years after maturation. 
Approximately 46.4% of patients with matured AVFs continued to use their AVFs for dialysis 
and 28.4% of patients died, had a kidney transplant, or transferred to peritoneal dialysis. AVF 
abandonment occurred most frequently in the 3rd month of dialysis (31.5%). Over 74.8% of 
AVFs were abandoned at the end of 6 months of dialysis. The median secondary functional 
patency was 3 months (IQR: 2-7) (Figure 3D). 
Among the AVFs which maintained secondary patency, the total number of post-
maturation revisions ranged from 0 to 27 with the median of 2 (IQR: 1-5). The incident rate of 
access revisions ranged from 0 to 1.1 per patient per month with the median of 0.1 (IQR: 0-0.2) 






There existed moderate variations in AVF placement and patency loss by geographic 
region and ESRD network (Figure 4 and 5).  Especially, the Mid-Atlantic region had the lowest 
rate of AVF placement (35.6%) and the highest rate of AVF primary patency loss (84.2%). 
Accordingly, network 2, 4, and 7 had the lowest rate of AVF placement (33.0%, 30.5%, and 
33.6%, respectively) and network 2, 4, and 5 had the highest rate of AVF primary patency loss 
(84.6%, 83.6%, and 81.7%, respectively). This statistical significance persisted after adjusting 
for patient’s age, gender, race, comorbid conditions and functional status. On the contrary, the 
odds of placing AVF in older hemodialysis patients was the highest in the New England area 
(network 1) (48.0%; adjusted OR 1.63; 95% CI 1.46-1.83).  
The West had the lowest rate of AVF primary patency loss (72.3%, adjusted OR 0.59; 95% 
CI 0.48, 0.71) among all regions. Two highest rates of AVF primary patency loss were 65.3% in 
network 16 (Northwest states) and 68.5% for network 18 (Southern California). The New 
England, South and Southwest had higher abandonment rate than the other three regions. The 
rate of AVF abandonment was 32.8% in network 2 (New York) and 30.6% in network 16 
(Northwest states). AVF maturation, however, was not significantly different among geographic 
regions except the South a borderline significance in maturation rate (67.5%; adjusted OR 0.87; 
95% CI 0.77-0.98).   
 
Sensitivity Analyses 
In the subset of 2,574 patients who had an intervention during the same calendar month 
as the AVF maturation, there was uncertainty about whether the intervention occurred before 
maturation or after maturation since AVF use was reported monthly. Our primary analysis 
assumed that all interventions occurring during that month of AVF maturation were after 
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maturation. In sensitivity analysis, we assumed that all interventions during that month of 
maturation represented interventions to facilitate maturation. The new percentage of assisted 
maturation was 63.8%, increased from that in the primary analysis (55%). The number of 
interventions varied from 0 to 53 times with the median of 1 (IQR: 0-3) and the 99th percentile 
increased to 10.  Similarly, the incident rate of intervention increased slightly ranging from 0 to 
10.6 times per patient per month with the median of 0.2 (IQR: 0-0.4) (Table S2).  The 
percentage of patients experienced primary patency loss decreased slightly from 75.2% to 72.9%.  
 
DISCUSSION 
This is the first study to our knowledge that examines the AVF care continuum in a 
national sample of older hemodialysis recipients. Our study demonstrates only 13% of older 
patients who initiated dialysis with a CVC successfully completed the three process of AVF care, 
and maintained functionality 2 years after AVF maturation. A total of 55% the maturation was 
facilitated by one or more interventions. AVF functionality was also sustained by frequent 
revisions. The median time from dialysis initiation to AVF placement and from placement to 
maturation was 2 months (IQR: 1-4) and 5 months (IQR: 4-7). The median AVF primary and 
secondary functional patency was 2 months (IQR: 1-5) and 3 months (IQR: 2-7), respectively. 
There existed moderate geographic variations in AVF placement and patency. Geographic 
difference in AVF maturation was not evident. 
Our analyses reveal a surprising low number of patients had an AVF placed 3 years after 
dialysis initiation. Results of our study reflect even though the goal of “Fistula First”, that is, the 
AVF use in 65% of the prevalent hemodialysis patients, has been achieved, it is achieved 
because over 1/3 of patients (39% in 3 years) died while dialyzing with a CVC and these patients 
are no longer counted in the prevalent hemodialysis population. Current clinical guidelines 
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recommend referral for access creation 6 months prior to the start of hemodialysis. 
2
 
Nevertheless, merely 33% of the patients initiated dialysis have an AVF placed prior to dialysis.
1 
Of the AVFs created pre-dialysis, nearly half of them (47%) are created at the time approaching 
(within 90 days of) dialysis initiation.
7
 Lack of pre-dialysis nephrology care appears to contribute 
greatly to low rate of AVF placement.
7
 In our study, 33% of the patients without a permanent 
access placement at dialysis initiation had no or less than 6-month pre-dialysis nephrology care. 
Not only they miss the opportunity for AVF/AVG placement prior to dialysis, but CVC-
associated mortality diminishes their chance to have a permanent access placed once dialysis 
starts  
As mentioned before, it is critical to establish a useful AVF at the early stage of dialysis. 
Our study proves the great efforts made by the U.S. renal community to construct a functional 
AVF for older patients at the beginning of their dialysis. Nearly 84% of all AVFs placed in the 3 
years occurred in the first 6 months after initiating dialysis. Almost 69% of all maturation and 
associated pre-maturation interventions also occurred within the first half year of placement. 
However, because the estimated median time from dialysis initiation to AVF maturation is ~7 
months, longer survival is needed for an AVF to mature. Identifying a subset of older 
hemodialysis patients who have a lower risk for early mortality, e.g. those with younger age, less 
comorbidities, limited functional status, may allow sufficient time for maturation assist clinical 
decision-making of AVF placement.  
After placement, AVF outcomes were worse than those reported in the pre-“Fistula First” 
era. Firstly, the 2-year rate of AVF maturation (68.9%) obtained from our study is lower to those 
reported previously. Al-Jaishi et al., for example, in their meta-analysis of AVF outcomes in 
elderly hemodialysis patients, reported the rate of primary failure at 12 months was 23%.
6
  In 
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addition, AVFs in this study were matured in an average of 5.6 months, which was substantially 
longer than other published studies. Rayner et al reported the median maturation time for AVFs 
was 98 days in US from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
8
 Allon et 
al. showed an average maturation time for AVF was 87 days.
9
 The lower rate of AVF maturation 
and prolonged time to maturation in our study might be explained by changes in practice patterns 
after “Fistula First” policy. Patients who might not be candidates for AVF placement previously 
due to their inadequate anatomy are likely to have an AVF placed in the post-“Fistula First” era. 
Including these patients for AVF placement leads to reduced maturation rate and prolonged time 
to reach maturation. The results of our study are close to those reported by Biuckians et al. in 




Few studies have reported 2-year AVF patency rate in the U.S. older adults. Lok et al. 
showed the 1- and 5-year AVF secondary patency was 75.1% and  64.7% , respectively, for 
patients 65 years and older.
11
 Lee et al. showed the rate of secondary functional patency at 2 
years ranged from 57% to 85% in 173 hemodialysis patients from two academic centers.
12
 While 
our 2-year rate of secondary patency is close to previous estimates, the primary patency rate in 
our study is much lower. This might be explained by increasing use of surgical and endovascular 
techniques to maintain AVF patency. Lee et al. showed AVFs required assistance to mature had 
similar secondary patency but higher frequency of interventions and were more likely to have 
primary patency loss.
13
 When an AVF is created in patients who have inadequate anatomy, it is 
more likely that an aggressive approach is used to maintain AVF patency to match the “Fistula 
First” prevalence goal. In our study, 23% of AVFs lost their secondary patency. This 
demonstrates that even if an AVF is matured and used for dialysis, only 77% were functioning 
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after 2 years. This may seem acceptable in regards to the KDOQI standards, but if we considered 
those who did not have an AVF placed and those never achieved a functional AVF, only 13 out 
of 100 patients initiated dialysis still use an AVF.   
Our study indicates geographic disparities in AVF outcomes in the post-“Fistula First” 
era which have not been reported before. Two analyses reported substantial geographic 
variations in prevalence of AVF use in the U.S. adult hemodialysis patients before the “Fistula 
First” policy. Hirth et al. reported the prevalence of AVF use varied considerably from a high of 
77% in New England to a low of 15% in the Southeast.
14 
Allon et al. reported geographic 
variations in the prevalence of AVF use among 1,824 U.S. adult patients enrolled in the HEMO 
Study ranging from 45.3% in the Northeast to 30.6% in the Southeast.
15
 It is interesting to notice 
that the crude rate of AVF maturation is not significantly different by geographic region whereas 
AVF placement and patency loss are affected by practice patterns. 
Our study has several limitations. First, we relied on AVF modifier codes or types of 
access used on the reported dialysis session to ascertain AVF maturation and patency. Access 
type reported from the dialysis claim may not reflect the AVF most frequently used for dialysis 
in the month. These codes were submitted by dialysis facilities for billing purpose and thus likely 
to be subjected to misclassification bias. Second, we cannot distinguish an upper arm AVF from 
a forearm AVF since the CPT codes of AVF placement do not provide data on the location of an 
AVF creation. Third, this study only includes elderly patients (≥67 years) in US and results of 
this study may not be generalizable to younger dialysis patients or patients in other countries.  
In conclusion, low percentage of older incident hemodialysis patients in the U.S. have 
successfully completed the all processes of AVF care and remained patent for dialysis. Future 
efforts to increase the prevalence of AVFs in older hemodialysis patients should focus on early 
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placement in the proper candidates.  Disparities in practice patterns needed to be addressed to 
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Table 1. Baseline characteristics of three study cohorts of elderly patients who initiated 









 Cohort 1 Cohort 2 Cohort 3 
Total cohort 43,851 14,892 7,528 
Demographics    
Age at dialysis initiation (yrs)(mean±SD) 77.1±6.7 76.7±6.5 76.6±6.4 
     67-<75 17,370(39.6) 6,196(41.6) 3,158(42) 
     75-<85 19,536(44.6) 6,641(44.6) 3,373(44.8) 
     ≥85 6,945(15.8) 2,055(13.8) 997(13.2) 
Gender    
     Male 22,990(52.4) 8,115(54.5) 4,524(60.1) 
     Female 20,861(47.6) 6,777(45.5) 3,004(39.9) 
Race    
     White 33,067(75.4) 11,322(76) 5,798(77) 
     Black 8,747(20) 2,755(18.5) 1,270(16.9) 
     Other/unknown 20,37(4.7) 815(5.5) 460(6.1) 
Region    
     Northeast 7,781(17.7) 2,386(16) 1,195(15.9) 
     Midwest 11,017(25.1) 3,941(26.5) 2,021(26.9) 
     South 16,800(38.3) 5,890(39.6) 2,872(38.2) 
     West 7,979(18.2) 2,610(17.5) 1,414(18.8) 
Comorbid conditions    
Primary cause of renal failure    
    Hypertension/Large vessel disease 15,454(35.2) 5,453(36.6) 2,762(36.7) 
    Diabetes 17,024(38.8) 6,236(41.9) 3,092(41.1) 
    Glomerulonephritis  1,351(3.1) 527(3.5) 309(4.1) 
    Other 10,022(22.9) 2,676(18) 1,365(18.1) 
Diabetes 28,646(65.3) 10,235(68.7) 5,035(66.9) 
Hypertension 32,564(74.3) 12,839(86.2) 6,441(85.6) 
Coronary artery disease 27,839(63.5) 9,533(64) 4,703(62.5) 
     Myocardial infarction 11,347(25.9) 3,665(24.6) 1,722(22.9) 
     Atherosclerosis 26,750(61) 9,227(62) 4,552(60.5) 
     Coronary revascularization 2,576(5.9) 854(5.7) 425(5.7) 
Congestive heart failure 30,619(69.8) 10,463(70.3) 5,101(67.8) 
Peripheral vascular disease 23,052(52.6) 7,848(52.7) 3,835(50.9) 
Cerebrovascular disease 13,594(31) 4,670(31.4) 2,297(30.5) 
Stroke 5,865(13.4) 1,785(12) 827(11) 
Chronic obstructive pulmonary disease 16,822(38.4) 5,757(38.7) 2,754(36.6) 
Cancer 8,951(20.4) 2,968(19.9) 1,518(20.2) 
Depression 7,633(17.4) 2,437(16.4) 1,136(15.1) 
Dementia 3,627(8.3) 995(6.7) 463(6.2) 
Functional status    
Amputation 673(1.5) 191(1.3) 98(1.3) 
Inability to ambulate 5,578(12.7) 1,239(8.3) 500(6.6) 
Inability to transfer 3,342(7.6) 616(4.1) 238(3.2) 
Needs assistance with daily activities 9,569(21.8) 2,552(17.1) 1,134(15.1) 
Institutionalized 7,803(17.8) 1,835(12.3) 759(10.1) 
Lab values    
Body mass index (kg/m2)(mean±SD) 28.2±7.3 28.5±7.3 28.2±7 
Hemoglobin (g/dl, mean ± SD) 10±13.8 10±13.6 10.2±18.9 
Serum albumin (g/dl, mean ± SD) 3.1±3.7 3.2±5.5 3.3±6.4 












Care patterns    
Nephrology care    
     No care 22,806(52) 6,799(45.7) 3,385(45) 
     0-6 months 6,318(14.4) 2,311(15.5) 1,188(15.8) 
     6-12 months 6,355(14.5) 2,393(16.1) 1,233(16.4) 
     12 months 8,372(19.1) 3,389(22.8) 1,722(22.9) 
Facility type    
     Hospital-based 4,045(9.3) 1,320(8.9) 734(9.8) 
     Freestanding 39,701(90.8) 13,532(91.1) 6,776(90.2) 
Profit status    
     For-profit 36,430(83.3) 12,460(83.9) 6,162(82.1) 
     Non-profit 6,913(15.8) 2,316(15.6) 1,311(17.5) 
     Unknown 403(0.9) 76(0.5) 37(0.5) 
GFR: Glomerular filtration rate. Missing values in cohort 1, 2, and 3 respectively:  BMI (0.8 %, 0.6%, and 
0.6%); hemoglobin (8.8%, 8.5%, and 8.4%); albumin (27%, 26.3%, and 25.9%); GFR (4.6%, 3.2%, and 







Table 2. Number and incident rate of pre-maturation interventions in patients with maturated 













End point N Mean STD Median IQR Min Max 
Pre-maturation interventions 10,260 1.4 2.2 1 0-2 0 42 
Incident rate of pre-maturation 
interventions (per patient per month) 
10,260 0.2 0.3 0.1 0-0.3 0 8.4 
        
Post-maturation revisions 3,352 3.1 3.4 2 1-5 0 27 
Incident rate of post-maturation revisions 
(per patient per month) 











14,892 had AVF placement within 6 months of HD 
initiation 
7,528 matured in 6 months 
201,309 initiated HD 2-year period 
 
57,137 used CVC only without a maturing AVF/AVG 
43,851 had no previous AVF/AVG surgeries using 2 
years of pre-ESRD claims 
92,104 were ≥67 years old 
 
46,764 had at least 1 inpatient/outpatient Medicare 
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Figure 2. Care continuum of arteriovenous fistula (AVF) among older adults undergoing 
hemodialysis including AVF placement within 3 years of dialysis initiation, AVF maturation 


















Figure 3. Monthly distribution of arteriovenous fistula (AVF) outcomes in older U.S. 
hemodialysis recipients. (A) AVF placement within 3 years of dialysis initiation; (B) AVF 
maturation within 2 years of replacement; (C) AVF primary patency loss within 2 years of 










(A) Fistula Placement 
N = 17,271 
Mean ± SD: 3.7 ± 4.5 months 
Median (IQR): 2(1-4) months 
 






(B) Fistula Maturation 
N=10,260 
Mean ± SD: 5.6 ± 3.4 months 
Median (IQR):5(4-7) months 






(C)Fistula Primary Patency Loss 
N=5,664 
Mean ± SD: 4.3±4.7 months 
Median (IQR): 2(1-5) months 









Within Month(s) of Fistula Maturation 
(D)Fistula Abandonment 
N=1,847 
Mean ± SD: 5.4 ± 5.1 months 






Figure 4. Distribution of arteriovenous fistula (AVF) outcomes by geographic region in older U.S. hemodialysis recipients. (A) AVF 
placement within 3 years of dialysis initiation; (B) AVF maturation within 2 years of replacement; (C) AVF primary patency loss 





















































    
     





















































Figure 5. Adjusted odds ratios (ORs) and associated 95% confidence intervals (CIs) for arteriovenous fistula (AVF) outcomes by 
geographic region in older U.S. hemodialysis recipients. (A) AVF placement within 3 years of dialysis initiation; (B) AVF maturation 
within 2 years of replacement; (C) AVF primary patency loss within 2 years of maturation; (D) AVF abandonment within 2 years of 



















Type of intervention Codes 
Open surgical procedures CPT-4 Codes 
Revision, open, arteriovenous fistula; with thrombectomy, autogenous or 
nonautogenous dialysis graft  
36833 
Revision of fistula or graft  36832 
Fistula elevation or superficialization 36832 
Ligation of accessory veins 36832 
Open surgical procedures for treatment of steal syndrome 36832 
Open repair of pseudoaneurysm 36832 
Banding fistula or graft 36832 
Open thrombectomy, arteriovenous fistula without revision, autogenous or 
nonautogenous dialysis graft 
36831  
 
Endovascular interventions CPT-4 Codes 
Angiogram with venous angioplasty 36147, 35476, 75978  
Angiogram with arterial angioplasty 36147, 35475, 75962 
Angiogram with venous angioplasty and stent 36147, 37205, 37206 (rarely +37239) 
Angiography, arteriovenous shunt (e.g., dialysis patient fistula / graft) 75791 (must be present with other interventions) 
Percutaneous thrombectomy 36870 (also 36147, 36148) 
Percutaneous thrombectomy with venous angioplasty 36870, 36147, 36148, 35476, 75978 
Percutaneous thrombectomy with arterial angioplasty 36870, 36147, 36148, 35475, 75962 
Percutaneous thrombectomy with venous angioplasty and stent 36870, 36147, 36148, 37205, 37206 (rarely +37239) 
 
Inpatient procedures  ICD-9 Codes 
Compression of vein 459.2 
Mechanical complications of vascular device, implant and graft 996.1 








Table S2. Frequency and incident rate of pre-maturation interventions in patients with matured 












 N Mean STD Median IQR Min Max 
Pre-maturation interventions 
 
10,260 1.7 2.3 1 0-3 0 53 
Incident rate of pre-maturation interventions 
(per patient per month) 








AGE AND ARTERIOVENOUS FISTULA PLACEMENT, MATURATION, 





Rational & Objective: Choosing the optimal vascular access for older adults on hemodialysis is 
challenging. Precisely estimation of the effect of age on arteriovenous fistula (AVF) outcomes 
provides valuable information for clinical decision making. Our study aimed to determine the 
association of age with AVF placement, maturation, and primary and secondary patency loss in 
the U.S. older hemodialysis recipients.  
Study Design: Retrospective cohort study 
Setting & Participants: Three national cohorts of incident hemodialysis patients aged 67 years 
and older who initiated dialysis (43,851), had an AVF placed (14,892), or had the placed AVF 
matured (7,528) assembled from the United States Renal Data System  
Exposure: Age at dialysis initiation 
Outcomes: AVF placement, maturation, primary and secondary patency loss  
Analytical Approach: Cause-specific and subdistribution proportional hazards models were 
used to examine the association of age and AVF outcomes with kidney transplantation, 
peritoneal dialysis, and death treated as competing events. Restricted cubic splines were used to 
identify cut-off values for age categorization. We compared crude and inverse probability 
weighted cumulative incidence function curves by Gray’s test. 
Results: Patients ≥77 years old had significantly lower probabilities of AVF placement (adjusted 
cHR 0.96, 95% CI 0.92-0.99; adjusted sHR 0.92, 95% CI 0.89-0.95; Gray’s test p<.0001) and 
maturation (adjusted cHR 0.95, 95% CI 0.91-0.99; adjusted sHR 0.93, 95% CI 0.90-0.97; 
p<.0001) as compared to those 67-<77. However, age is not associated with AVF primary 
patency loss (adjusted cHR 1.05, 95% CI 1.00-1.11; adjusted sHR 1.04, 95% CI 0.99-1.09; 
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p=0.091) or secondary patency loss (adjusted cHR 1.05, 95% CI 0.95-1.15; adjusted sHR 1.03, 
95% CI 0.94-1.13; p=0.613).  
Limitations: Vascular access ascertainment 
Conclusion: The likelihood of AVF maturation should be the most important consideration for 
vascular access planning in older hemodialysis recipients. AVF might not the best vascular 





Older adults are the fastest growing segment of the prevalent population with end-stage 
kidney disease (ESKD). In 2016, 47.4% of U.S. patients undergoing hemodialysis therapy were 
65 years or older
1
as compared to 44.7% in 2010.
2
 Older dialysis recipients present a special 
challenge to ESKD care community because of their heavy comorbid burdens, limited functional 
and cognitive ability, and shorten life expectancy.
3,4
  
Current clinical guidelines recommend the arteriovenous fistula (AVF) as the optimal 
type of vascular access for hemodialysis.
5
 This recommendation was based on observational data 
that AVF, once functional, are less prone to infection and are associated with reduced all-cause 
mortality as compared to arteriovenous graft (AVG) and central venous catheters (CVC).
6,7
 In 
older dialysis recipients, matured AVF achieves longer patency and requires less interventional 
procedures to maintain functionality as compared to AVG.
8
 In the short-term, however, AVF is 
less likely to mature and needs higher frequency of interventions to achieve maturation as 
compared to AVG.
8
 This leads to prolonged CVC use, which is related to substantially elevated 
rates of infection
 9,10
 and increased all-cause mortality.
11,12
 Older patients, especially those who 
are likely to have short life expectancy and worse AVF outcomes, face the dilemma whether they 
should have an AVF or AVG placed as the primary vascular access. So far there is no clear 
clinical recommendation for AVF placement using age as a criterion and clinical decision is left 
to vascular surgeon’s individual decision.  
In general, evidence on the association of age and AVF outcomes was scarce in the 
literature. Definitions of “elderly” in these studies are often inconsistent and the results of AVF 
outcomes are conflicting. This study aims to examine the association of age with AVF outcomes 
including AVF placement, maturation, and primary and secondary patency loss in the U.S. older 
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adults undergoing hemodialysis. Precisely estimation of the effect of age on AVF outcomes 
provides valuable information to assist individual vascular access plan development.  
 
METHODS  
Data Source and Study Population  
Our primary data source was derived from the 2010-2015 United States Renal Data 
System (USRDS) standard analytic files (SAFs).  Figure 1 demonstrated development of our 
study cohorts.  Cohort 1, the hemodialysis cohort, included 43,851 incident hemodialysis 
recipients aged 67 years and older who initiated dialysis through a CVC between 7/1/2010 and 
6/30/2012. To ensure that the CVC was the only vascular access present at the start of dialysis 
therapy, patients were excluded if they: (1) were using an AVF or AVG or had an AVF or AVG 
placed but were awaiting maturation at dialysis initiation, as reported in the Medical Evidence 
Form; (2) underwent AVF or AVG surgery in the 2-year pre-end stage renal disease (ESRD) 
period, as assessed by Current Procedural Terminology-4 (CPT-4) procedure codes of 36818, 
36819, 36820, 36821, and 36825 for AVF and 36800, 36810, and 36830 for AVG. From the 
hemodialysis cohort (cohort 1), we further identified two subcohorts. Cohort 2, the AVF placed 
cohort, included 14,569 patients who had an AVF placement within 6 months after dialysis 
initiation. Cohort 3, the AVF matured cohort, included 7,301 patients whose AVFs matured 
within 6 months after placement.  
 
Study Outcomes 
The primary outcomes of this study were AVF placement (cohort 1), AVF maturation 
(cohort 2), and AVF primary and secondary patency loss (cohort 3). We identified AVF 
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placement from the physician/supplier claims and institutional claims files, which record the 
exact date of AVF construction, by using the same CPT-4 codes as listed above. Different from 
AVF placement, AVF maturation and patency loss were ascertained by month. AVF maturation 
was determined by using the first vascular access modifier code ‘V7’ reported from the 
institutional details claims file or the first AVF used with two needles reported from the 
Crownweb clinical file. We defined AVF primary patency loss as the first revision procedure 
after maturation. Codes used to identify intervention procedures were listed in Table S1. We 
defined AVF secondary patency loss (abandonment) as 3 consecutive months of CVC use or a 
new vascular access placement. Cohort 1 was followed for 3 years from dialysis initiation. 




A competing event in this study was defined as kidney transplantation, peritoneal dialysis 
transfer, or death, whichever occurred first in the follow-up period.  Competing events were 
determined by using the transplant file, dialysis institutional claims file, and death file, 
respectively. 
 
Covariates of Interest 
Age at dialysis initiation was study exposure. We extracted patient demographics, 
residential region, BMI, functional status, lab values, primary cause of renal failure, and pre-
dialysis nephrology care from the Medical Evidence Form. In addition, 2-year pre-ESRD claims 
files were used to identify major comorbid conditions. ESRD network number, facility profit 
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status, and hospital association were ascertained from the facility file and merged to patient-level 




We presented summary statistics as frequency and percentages for categorical data and 
means ± SDs for continuous variables by patient’s age at dialysis initiation. In each cohort, we 
classified patients into three mutually exclusive groups according to whether they experienced 
the outcome of interest (AVF placement, maturation, primary patency loss, and abandonment) or 
a competing event: (1) patient experienced the outcome of interest; (2) patient had a competing 
event; and (3) patient did not experience the outcome of interest or a competing event. To 
properly categorize the continuous age into groups, we tested the assumption of a linear 
relationship between age and log hazard ratios of AVF outcomes by using restricted cubic spline 
function.
13,14
 Any breakpoint in linearity or change in slope of cubic splines was viewed as a 
change in effect of age on AVF outcomes. We tested different knot numbers and locations and 
selected spline functions with 3 knots at 10th, 50th, and 90th percentile. When evidence of a 
non-linear relationship was found, we identified the break points and used them to categorize age. 
We used the cause-specific and subdistribution proportional hazards models to explore the 
possible association between age group and AVF outcomes. Two sets of cause-specific hazard 
ratios (cHRs) and subdistribution hazard ratios (sHRs), the first for AVF outcomes and the 
second for competing events, were reported.
 15
 Specifically, the cHRs of AVF outcomes were 
calculated with competing events censored and the cHRs of competing events were obtained 
with AVF outcomes censored. The proportional hazards assumption was checked by examining 
age and time interaction and by plotting log of negative log of estimated survival function versus 
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log of time in the cause-specific models. When the proportional hazards assumption is satisfied, 
the graph should show parallel lines and the statistical test of age and time interaction should be 
insignificant. To accommodate any violation of proportional hazards assumption, we also 
generated the non-parametric inverse probability weighted cumulative incidence function (CIF) 
curves
16
 and implemented Gray’s test for equivalence of CIF to compare weighted cumulative 
incidence by age groups. Inverse probability weights are the inverse of propensity scores, which 
are the estimated probabilities of treatment assignment conditioned on covariates. Different from 
the log-rank test for cause-specific hazards, Gray’s test accesses the absolute difference in 
incidence of events between age groups.
17
 Statistical analyses were performed using SAS 
(version 9.4; SAS institute, Cary, NC). All statistical tests were two-sided, and a p-value < 0.05 
considered statistically significant. Institutional review board approval for an exempt review was 
obtained from Bloomberg School of Public Health at Johns Hopkins University. We used the 





Figure S1 indicated that only effect of age at dialysis initiation on the log hazard ratios of 
AVF placement was not linear (p<.0001). Age 76 or 77 corresponded to a break point in the 
splines. Effect of age between 67-<77 was homogenous, but after 77, hazard ratios of AVF 
placement decreased rapidly with age. Accordingly, we assumed effect of age on hazard ratios of 
AVF placement after 77 was same and chose age of 77 as a convenient cut-off value to classify 





Table 1 listed patient demographics, comorbid conditions, functional status, lab values, 
and care patterns by two categories of age at dialysis initation. Patients 67-<77 years old were 
more likely to be male (53.1% vs. 51.8%) and Black (23.2% vs. 16.7%) as compared to those 
≥77.  Not surprisingly, patients aged ≥77 years old carried higher comorbid burdens and had 
worse functional status, as compared to those 67-<77. Nutrition status (hemoglobin and serum 
albumin values) and practice patterns were similar between two age groups.  
 
Age and AVF Placement 
Of 43,851 patients who initiated dialysis with a CVC in the hemodialysis cohort (cohort 
1), 39.4% of them had an AVF placed within 3 years of dialysis initiation, 40.8% experienced a 
competing event, and 19.8% kept dialyzing with a CVC or had other forms of vascular access 
placed (Table 2).  As compared to patients 67-<77, those ≥77 years old had significantly lower 
probability to have an AVF placed (unadjusted cHR 0.93, 95% CI 0.90-0.96; adjusted cHR 0.96, 
95% CI 0.92-0.99; unadjusted sHR 0.86, 95% CI 0.84-0.89; adjusted sHR 0.92, 95% CI 0.89-
0.95) but higher probability of experiencing a competing event (unadjusted cHR 1.36, 95% CI 
1.32-1.40; adjusted cHR 1.19, 95% CI 1.15-1.24; unadjusted sHR 1.36, 95% CI 1.32-1.40; 
adjusted sHR 1.20, 95% CI 1.16-1.25) (Table 3A and 3B). Results of Gray’s test for equality of 
weighted CIF also confirmed age was statistically significantly associated with AVF placement 




Age and AVF Maturation 
In the AVF placed cohort (cohort 2), 68.9% of 14,892 patients achieved AVF maturation, 
20.3% experienced a competing event, and 10.8% maintained on dialysis without a matured 
AVF 2 years after AVF placement (Table 2). Proportional hazards regressions showed AVFs 
placed in patients ≥77 years old were less likely to mature as compared to those in patients 67-
<77 (unadjusted cHR 0.95, 95% CI 0.91-0.99; adjusted cHR 0.95, 95% CI 0.91-0.99; unadjusted 
sHR 0.91, 95% CI 0.87-0.94; adjusted sHR 0.93, 95% CI 0.90-0.97) (Table 3A and 3B).  They 
were more likely to have a competing event (unadjusted cHR 1.33, 95% CI 1.24-1.43; adjusted 
cHR 1.17, 95% CI 1.08-1.26; unadjusted sHR 1.35, 95% CI 1.25-1.45; adjusted sHR 1.19, 95% 
CI 1.10-1.28) (Table 3A and 3B).  Gray’s test also demonstrated the association of age and AVF 
maturation was statistically significant (p<.0001) (Figure 2). 
 
Age and AVF Primary Patency Loss 
Among 7,528 patients in the AVF matured cohort (cohort 3), 75.2% of them experienced 
AVF primary patency loss, and 13.9% had a competing event (Table 2). Cause-specific hazards 
analyses showed age was significantly associated with AVF primary patency loss (unadjusted 
cHR 1.05, 95% CI 1.00-1.11; adjusted cHR 1.05, 95% CI 1.00-1.11) (Table 3A). However, both 
the subdistribution hazards regressions and Gray’s test revealed difference in AVF primary 
patency loss was not statistically significant by age groups (unadjusted sHR 1.03, 95% CI 0.98-
1.08; adjusted sHR 1.04, 95% CI 0.99-1.09; p=0.091) (Table 3B and Figure 2).  Age patients 
≥77 years old were more likely to have a competing event as compared to those 67-<77 
(unadjusted cHR 1.44, 95% CI 1.25-1.65; adjusted cHR 1.12, 95% CI 0.99-1.27; unadjusted sHR 




Age and AVF Abandonment 
Overall 25.2% of matured AVFs in the AVF matured cohort (cohort 3) were abandoned. 
Approximately half (46.4%) of patients with matured AVFs continued to use their AVFs for 
dialysis and 28.4% of patients experienced a competing event 2 years after AVF maturation 
(Table 2). Age was not associated with an increased risk for AVF abandonment (unadjusted 
cHR 1.07, 95% CI 0.98-1.17; adjusted cHR 1.05, 95% CI 0.95-1.15; unadjusted sHR 1.04, 95% 
CI 0.95-1.14; adjusted sHR 1.03, 95% CI 0.94-1.13; p=0.613) but patients ≥77 years old had 
higher likelihood of experiencing a competing event (unadjusted cHR 1.48, 95% CI 1.35-1.61; 
adjusted cHR 1.33, 95% CI 1.22-1.46; unadjusted sHR 1.43, 95% CI 1.31-1.56; adjusted sHR 
1.30, 95% CI 1.19-1.42) as compared to those 67-<77  (Table 3A and 3B and Figure 2).  
 
Proportional Hazards Assumption 
The proportional hazards assumption was violated when comparing AVF placement 
(p=0.014 and p<.0001 for time and age interactions in cause-specific and subdistribution models, 
respectively) and maturation (p<.0001 for both models) by age. Hazards appeared proportional 




To our knowledge, this study is the first national study in the older hemodialysis patients 
examining the association of age with AVF placement, maturation, and patency loss accounting 
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for the competing events of death, kidney transplant, and peritoneal dialysis transfer. Among the 
U.S. older adults who initiated dialysis with a CVC, patients ≥ 77 years old had significantly 
lower probability of getting an AVF placed in 3 years after dialysis initiation and matured in 2 
years after placement compared to those aged 67-<77. However, in the subcohort of patients with 
a matured AVF, AVF primary and secondary functional patency was not statistically different by 
age group (67-<77 vs. ≥ 77) in 2 years after maturation. 
These results are consistent with two national studies of effect of age on AVF placement 
and maturation among older adults initiating dialysis. 
18,19
 Lily et al. showed among the U.S. 
patients who initiated hemodialysis between 2005 and 2009, those aged 85 years and older had a 
lower odds of AVF maturation as compared to patients aged 65-<85 at their first dialysis 
session.
18
 Similarly, Harford et al. reported the odds of AVF maturation was significantly lower 
in ≥80 group compared to those aged 67-<80 at dialysis initiation between 2005 and 2010. 
19
 The 
effect of age on AVF maturation persisted in these two studies after adjusting for patient’s 
demographics, comorbid conditions, insurance status, prior nephrologist care patterns, BMI or 
functional status. However, these two studies estimated rate of AVF maturation in a cross-
sectional design without considering whether these patients had an AVF placed. Our study, 
instead, implemented a retrospective design and considered change in the risk set due to 
competing events so that we obtained a better estimation of impact of age on AVF placement and 
maturation.  Furthermore, studies by Lily and Harford examined AVF maturation at dialysis 
initiation so AVFs included in their studies were placed prior to dialysis. Our study extended 
their analyses by assessing AVF placement and maturation among older adults who initiated 
dialysis without a permanent vascular access. Compared to those dialyzed with an AVF or AVG, 
these patients are more susceptible to the greatly increased risk of infection-related 
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hospitalizations and all-cause mortality due to CVC use. 
20
 Our findings of differentiate rates in 
AVF placement and maturation by age provided valuable information for future vascular access 
planning and policy making in this particular group. 
Our findings concur with the conclusions drawn from three retrospective single-center 
studies that older age did not increase the risk of AVF patency loss.
21, 22, 23
 In a single-center 
study of 335 patients, Swindlehurst et al. reported the 25-month AVF primary and secondary 
patency rates were not significantly different between adult patients ≥65 years old and those 
<65.
21
 Another study by Weale et al. also indicated age group (<65, 65 to 79, ≥80) was not 
associated with the 1- and 2-year primary and secondary patency among 658 adult patients.
22
 
Similar to our study, these two studies included both radiocephalic (wrist or forearm) and 
brachiocephalic (upper arm) AVFs. Nonetheless, patients in these two studies were enrolled after 
ultrasound vessel screening so they were more likely to have homogeneous vein parameters 
regardless of age. In the third study of 444 incident AVF patients by Lok et al., preoperative vein 
mapping was not necessarily performed. Their study also proved the 1- and 5- year AVF 
secondary patency was not significantly different between patients ≥65 and <65.
23
 Our study 
added to the evidence by extending the findings from these single-center studies to a national 
cohort of patients from dialysis facilities with distinct practice patterns at various geographic 
locations.  
Our study revealed that patients aged 77 and older had lower probability of AVF 
placement and maturation as compared to those aged 67-<77 after controlling for patient’s 
demographic, comorbid conditions, functional status, and facility practice patterns.  Notably, 
even though a greater number of patients in the age ≥77 group were removed from the risk set 
due to the competing events, the resulting cumulative incidence of AVF placement and 
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maturation were still lower than that in the 67-<77 group.  This indicated the unwillingness of 
dialysis facilities to refer patients in this age group to AVF placement and the lower likelihood of 
AVF maturation even though patients in the ≥ 77 group have comparable comorbid profile and 
functional status as their younger counterparts.  Our study showed these patients are more likely 
to experience a competing event than have an AVF placed or matured. Our study also 
demonstrated, once matured, AVFs placed in those aged ≥77 attained similar primary and 
secondary patency as compared to those in aged 67-<77.  This suggested AVF maturation is the 
greatest barrier between the initial step of AVF placement and achieving the goal of patency 
attainment. In other words, the decision of “Fistula First” in older dialysis patients should be 
made based on the estimated likelihood of AVF maturation.  
Nationally, the average life expectancy for patients on dialysis aged 80 to 84, and 85 
years and older were 2.7 and 2.2 years, respectively.
1
 Even matured, AVF use in patients ≥ 77 
years old for a short period of time may not worth the risk of dialyzing with a CVC while 
waiting for AVF to mature. For dialysis patients approaching eighty year old, AVG may be a 
better alternative since it takes much less time to reach successful use (~ 2 to 4 weeks) and the 
associated all-cause mortality were not significantly different from that of AVF placement.
24
 On 
the other hand, our study supports placing AVF as the initial vascular access in patients 67 to 76 
years old.  Hemodialysis patients aged 70 to 74 and 75-79 are expected to live up to 3.8 and 3.3 
years on average.
1
 If life expectancy estimated based on an individual’s frailty, clinical situation, 
and comorbid condition is more than 2 years, AVF placement might bring overall benefits. 
Our study has several strengths. Competing risk is a crucial consideration in studies of 
older adults undergoing dialysis because of high mortality and frequent switch in therapy. 
Methods which fail to account for the presence of these competing risks like standard survival 
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analysis can overestimate the probability of AVF outcomes.
25
 In this study, we used the 
cumulative incidence competing risk estimate and competing risk regressions to determine the 
association of age and AVF outcomes. Compared to the method using traditional survival 
analysis, our study provided precise estimations of effects of age on AVF outcomes and printed a 
full picture to better describe data and interpret results.  Moreover, the cutoff values of age were 
often arbitrarily selected in previous studies so that the effect of age on AVF outcomes was 
forced to be homogenous within each category. Our study, instead, chose the cutoff point of 77 
to categorize age based on the change in the slope of the log hazard ratio function.  
However, several limitations should be noted. First, we relied on AVF modifier codes or 
types of access used on the reported dialysis session to ascertain AVF maturation and patency. 
These codes were submitted by dialysis facilities for billing purpose and thus likely to be 
subjected to misclassification and selection bias. Secondly, although we adjusted for all available 
patient characteristics measured in claims data, it is possible that poorer vascular access 
outcomes among patients who initially received an AVF is the result of other factors (e.g. AVF 
location
28
 and vein diameter
26,27
) instead of patient demographics and comorbid conditions. 
Unmeasured confounding likely exist since USRDS does not collect all known risk factors which 
are associated with choice of vascular access and AVF outcomes.  
In conclusion, our retrospective analysis of a nation cohort encompassing older adults 
who initiated dialysis with a CVC shows increased age is associated with reduced probabilities 
of AVF placement and maturation but not AVF primary and secondary patency loss. In clinical 
practice, the likelihood of AVF maturation should be the most important consideration for 
vascular access planning in older hemodialysis recipients. For older patients approaching or over 
eighty years old, AVG could be an alternative primary vascular access. Future studies are needed 
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to better predict AVF maturation in this population and to improve shared decision-making 
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Table 1.  Patient demographics, comorbid conditions, functional status, lab values, and care 
patterns by age groups in old patients initiating dialysis with a catheter.  
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 Age at dialysis initiation 
 67-<77 ≥77 
Total   
Demographics   
Gender   
     Male 11,526(53.1) 11,464(51.8) 
     Female 10,196(46.9) 10,665(48.2) 
Race   
     White 15,660(72.1) 17,407(78.7) 
     Black 5,042(23.2) 3,705(16.7) 
     Other/unknown 1,020(4.7) 1,017(4.6) 
Region   
     Northeast 3,425(15.8) 4,356(19.7) 
     Midwest 5,344(24.7) 5,673(25.6) 
     South 8,864(40.8) 7,936(35.9) 
     West 3,938(18.1) 4,041(18.3) 
Comorbid conditions   
Comorbid score 8.8±4.6 9.5±4.5 
Primary cause of renal failure   
    Hypertension/Large vessel disease 6,191(28.5) 9,263(41.9) 
    Diabetes 9,917(45.7) 7,107(32.1) 
    Glomerulonephritis  656(3) 695(3.1) 
    Other 4,958(22.8) 5,064(22.9) 
Diabetes 15,452(71.1) 13,194(59.6) 
Hypertension 15,824(72.9) 16,740(75.7) 
Coronary artery disease 13,259(61) 14,580(65.9) 
     Myocardial infarction 5,531(25.5) 5,816(26.3) 
     Atherosclerosis 12,731(58.6) 14,019(63.4) 
     Coronary revascularization 1,386(6.4) 1,190(5.4) 
Congestive heart failure 14,476(66.6) 16,143(73) 
Peripheral vascular disease 11,023(50.8) 12,029(54.4) 
Cerebrovascular disease 6,544(30.1) 7,050(31.9) 
Stroke 2,880(13.3) 2,985(13.5) 
Chronic obstructive pulmonary disease 8,257(38.1) 8,565(38.7) 
Cancer 4,165(19.2) 4,786(21.6) 
Depression 3,984(18.3) 3,649(16.5) 
Dementia 1,230(5.7) 2,397(10.8) 
Functional status   
Amputation 448(2.1) 225(1) 
Inability to ambulate 2,515(11.6) 3,063(13.8) 
Inability to transfer 1,488(6.9) 1,854(8.4) 
Needs assistance with daily activities 4,122(19) 5,447(24.6) 
Institutionalized 3,191(14.7) 4,612(20.8) 
Lab values   
Body mass index (kg/m2)(mean±SD) 29.4±7.8 27±6.6 
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*eGFR: estimated glomerular filtration rate. 
  
Hemoglobin (g/dl, mean ± SD) 10.1±16 10±11.2 
Serum albumin (g/dl, mean ± SD) 3.1±4.3 3.1±3.1 
eGFR (ml/min/1.73 m2,  mean ± SD)* 13.2±5.8 13.9±5.7 
Care patterns   
Nephrology care   
     No or less than 6 months 14,463(66.6) 14,661(66.3) 
     6-12 months 3,204(14.8) 3,151(14.3) 
     12 months 4,055(18.7) 4,317(19.5) 
Facility type   
     Hospital-based 1,956(9) 2,089(9.5) 
     Freestanding 19,716(91) 19,985(90.5) 
Profit status   
     For-profit 18,143(83.7) 18,287(82.8) 
     Non-profit 3,348(15.5) 3,565(16.2) 







Table 2. Numbers and percentages of arteriovenous fistula (AVF) outcomes including AVF 
placement in 3 years after dialysis initiation,   AVF maturation in 2 years after placement, and 
AVF primary patency loss and abandonment in 2 years after maturation by age group in 








 AVF placement Died/TX/PD before AVF placement No event 
Total 17,271(39.4) 17,897(40.8) 8,683(19.8) 
 67-<77 9,074(41.8) 7,852(36.2) 4,796(22.1) 
 ≥77 8,197(37) 10,045(45.4) 3,887(17.6) 
 AVF maturation Died/TX/PD  before AVF maturation No event 
 10,260(68.9) 3,029(20.3) 1,603(10.8) 
67-<77 5,527(71.5) 1,369(17.7) 834(10.8) 
 ≥77 4,733(66.1)  1,660(23.2)  769(10.7)  
 AVF primary patency loss Died/TX/PD  before AVF primary patency loss No event 
 5,664(75.2) 1,045(13.9) 819(10.9) 
67-<77 2,957(74.6)  530(13.4) 475(12)  
≥77 2,707 (75.9)  515(14.4)  344(9.7)  
 AVF abandonment Died/TX/PD  before AVF abandonment No event 
 1,899(25.2)  2,137(28.4)  3,492(46.4)  
67-<77 984(24.8) 961(24.3) 2,017(50.9) 
≥77 915(25.7) 1,176(33) 1,475(41.4) 







Table 3A. Cause-specific hazard ratios (cHRs) and their associated 95% confidence intervals 
(CIs) of arteriovenous fistula (AVF) outcomes and competing events by age group in 





 AVF Outcomes Competing Events5 





cHR (95% CI) 
Adjusted cHR 
(95% CI) 
AVF placement1     
      67-<77 1 1 1 1 
      ≥77 0.93(0.90,0.96) 0.96(0.92,0.99) 1.36(1.32,1.40) 1.19(1.15,1.24) 
AVF maturation2     
      67-<77 1 1 1 1 
      ≥77 0.95(0.91,0.99) 0.95(0.91,0.99) 1.33(1.24,1.43) 1.17(1.08,1.26) 
AVF primary patency loss3     
      67-<77 1 1 1 1 
      ≥77 1.05(1.00,1.11) 1.05(1.00,1.11) 1.44(1.25,1.65) 1.12(0.99,1.27) 
AVF abandonment4     
      67-<77 1 1 1 1 
      ≥77 1.07(0.98,1.17) 1.05(0.95,1.15) 1.48(1.35,1.61) 1.33(1.22,1.46) 
Note: 1. Adjusted by gender, race, diabetes, hypertension, stroke, myocardial infarction, coronary 
revascularization, congestive heart failure, cardiovascular disease, cancer, comorbid score, body mass index 
(BMI), albumin, estimated glomerular filtration rate (eGFR), functional status, nephrology care, and region.  
2. Adjusted by gender, race, diabetes, myocardial infarction, stroke, cardiovascular disease, functional status, 
facility type, comorbid score, BMI, eGFR, time of central venous catheter (CVC) dependency, and primary or 
secondary AVF.  
3. Adjusted by gender, race, chronic obstructive pulmonary disease (COPD), depression, region, facility type, 
facility profit status, comorbid score, and eGFR.  
4. Adjusted by gender, race, hypertension, angina and atherosclerosis, congestive heart failure, peripheral 
vascular disease (PVD), stroke, COPD, cancer, depression, functional status, facility type, comorbid score, BMI, 
eGFR, and time of CVC dependency. 







Table 3B. Subdistribution hazard ratios (cHRs) and their associated 95% confidence intervals 
(CIs) of arteriovenous fistula (AVF) outcomes and competing events by age group in 








 AVF Outcomes Competing Events5 








AVF placement1     
      67-<77 1 1 1 1 
      ≥77 0.86(0.84,0.89) 0.92(0.89,0.95) 1.36(1.32,1.40) 1.20(1.16,1.25) 
AVF maturation2     
      67-<77 1 1 1 1 
      ≥77 0.91(0.87,0.94) 0.93(0.90,0.97) 1.35(1.25,1.45) 1.19(1.10,1.28) 
AVF primary patency loss3     
      67-<77 1 1 1 1 
      ≥77 1.03(0.98,1.08) 1.04(0.99,1.09) 1.09(0.97,1.23) 1.04(0.92,1.18) 
AVF abandonment4     
      67-<77 1 1 1 1 
      ≥77 1.04(0.95,1.14) 1.03(0.94,1.13) 1.43(1.31,1.56) 1.30(1.19,1.42) 
Note: 1. Adjusted by gender, race, diabetes, hypertension, stroke, myocardial infarction, coronary 
revascularization, congestive heart failure, cardiovascular disease, cancer, comorbid score, body mass index 
(BMI), albumin, estimated glomerular filtration rate (eGFR), functional status, nephrology care, and region.  
2. Adjusted by gender, race, diabetes, myocardial infarction, stroke, cardiovascular disease, functional status, 
facility type, comorbid score, BMI, eGFR, time of central venous catheter (CVC) dependency, and primary or 
secondary AVF.  
3. Adjusted by gender, race, chronic obstructive pulmonary disease (COPD), depression, region, facility type, 
facility profit status, comorbid score, and eGFR.  
4. Adjusted by gender, race, hypertension, angina and atherosclerosis, congestive heart failure, peripheral 
vascular disease (PVD), stroke, COPD, cancer, depression, functional status, facility type, comorbid score, BMI, 
eGFR, and time of CVC dependency. 












14,892 had AVF placement within 6 months of HD 
initiation 
7,528 matured in 6 months 
201,309 initiated HD 2-year period 
 
57,137 used CVC only without a maturing AVF/AVG 
43,851 had no previous AVF/AVG surgeries using 2 
years of pre-ESRD claims 
92,104 were ≥67 years old 
 
46,764 had at least 1 inpatient/outpatient Medicare 




AVF Placed Cohort 
Cohort 3 







Figure 2. Weighted cumulative incidence functions (CIF) of arteriovenous fistula (AVF) outcomes and competing events by age 
group in hemodialysis patients aged 67 and older. P values were obtained from Gray’s test for equality of weighted CIF. Bottoms lines: 
AVF outcomes including AVF placement in 3 years after dialysis initiation, AVF maturation in 2 years after placement, AVF primary 
patency loss in 2 years after maturation, and AVF abandonment in 2 years after maturation; top lines: competing events including 
















Table S1. Codes of surgical and endovascular procedures associated with hemodialysis 




Type of intervention Codes 
Open surgical procedures CPT-4 Codes 
Revision, open, arteriovenous fistula; with thrombectomy, autogenous or 
nonautogenous dialysis graft  
36833 
Revision of fistula or graft  36832 
Fistula elevation or superficialization 36832 
Ligation of accessory veins 36832 
Open surgical procedures for treatment of steal syndrome 36832 
Open repair of pseudoaneurysm 36832 
Banding fistula or graft 36832 
Open thrombectomy, arteriovenous fistula without revision, autogenous or 
nonautogenous dialysis graft 
36831  
 
Endovascular interventions CPT-4 Codes 
Angiogram with venous angioplasty 36147, 35476, 75978  
Angiogram with arterial angioplasty 36147, 35475, 75962 
Angiogram with venous angioplasty and stent 36147, 37205, 37206 (rarely +37239) 
Angiography, arteriovenous shunt (e.g., dialysis patient fistula / graft) 75791 (must be present with other interventions) 
Percutaneous thrombectomy 36870 (also 36147, 36148) 
Percutaneous thrombectomy with venous angioplasty 36870, 36147, 36148, 35476, 75978 
Percutaneous thrombectomy with arterial angioplasty 36870, 36147, 36148, 35475, 75962 
Percutaneous thrombectomy with venous angioplasty and stent 36870, 36147, 36148, 37205, 37206 (rarely +37239) 
 
Inpatient procedures  ICD-9 Codes 
Compression of vein 459.2 
Mechanical complications of vascular device, implant and graft 996.1 







Figure S1. Restricted cubic spline plots of log hazard ratio of arteriovenous fistula (AVF) outcomes versus age with 3 knots at 10th, 
50th, and 90th percentile. A restricted cubic spline is a cubic spline in which the splines are constrained to be linear in the two tails. 
Break points in the linearity are changes in slope for the log hazard ratio function. The dotted curves represent the 95% confidence 
intervals. (A) AVF placement in 3 years after dialysis initiation; (B) AVF maturation in 2 years after placement; (C) AVF primary 


















































VALIDATION OF A RISK EQUATION PREDICTING HEMODIALYSIS 





Background: Choice of vascular access for older hemodialysis patients presents a special 
challenge since the rate of arteriovenous fistula (AVF) primary failure is high. Although the 
Lok’s risk equation for AVF primary failure has achieved good prediction accuracy and holds 
great potential for clinical use, it has not been validated in the U.S. older hemodialysis patients. 
Methods:  We assembled a validation data set of 14,892 patients aged 67 years and older who 
initiated hemodialysis with a central venous catheter between 7/1/2010 and 6/30/2012 and had a 
subsequent, incident AVF placement from the United States Renal Data System. We examined 
the external validity of Lok’s model by applying it to the validation data set. The discriminatory 
accuracy and calibration were evaluated by the concordance index (C-statistics) and calibration 
plot, respectively. Results: The observed frequency of AVF primary failure varied from 0.45 to 
0.53 in hemodialysis patients in the validation data set. The predicted probabilities of AVF 
primary failure calculated by using the Lok’s risk equation ranges from 0.08 to 0.61 and 77.8%, 
40.5%, and 51.7% of patients were categorized as having high, intermediate, and low risk of 
AVF primary failure, respectively. C-statistics of the Lok’s risk equation in the validation data 
set was 0.53 (95% CI:  0.52 - 0.54). The predicted probabilities of AVF primary failure 
corresponded poorly with the observed proportions In the calibration plot. Conclusions: When 
externally applied to a cohort of the U.S. older hemodialysis patients, the Lok’s risk equation 
exhibited poor discrimination and calibration accuracy. It is invalid to use it to predict AVF 
primary failure. A more complex model with strong predictors is expected to better serve clinical 





Annually over 50,000 patients who are 65 years and older start hemodialysis in the 
United States. Choosing the primary vascular access for older dialysis patients is challenging. 
Although current clinical guidelines and the “Fistula First” campaign recommend arteriovenous 
fistula (AVF) as the optimal type of vascular access,
1,2
 older age is associated with higher 
probability of AVF primary failure.
3
 A failed AVF requires one or more salvage procedures to 
promote maturation which leads to prolonged dialysis dependence on central venous catheter 
(CVC). CVC is known as the most inferior vascular access type and associated with substantially 
elevated rates of infection
4,5,6
 and all-cause mortality.
7 
For older patients at great risk of AVF 
failure, an arteriovenous graft (AVG) might be an alternative vascular access choice for dialysis. 
A model which accurately predicts AVF primary failure in older dialysis patients based upon 
patient characteristics can assist better clinical decision-making for AVF placement.  
To date, few studies have especially developed models to predict AVF primary failure for 
older dialysis patients. The Lok’s risk equation for AVF primary failure was derived from a 
retrospective cohort of 422 Canadian hemodialysis adults with a first-time AVF placement.
8
  
Compared with other available prediction models, the Lok’s risk equation holds great potential 
for clinical use. The equation incorporates 4 binary predictors (patient age ≥ 65, white race, and 
history of peripheral vascular disease (PVD) and coronary artery disease (CAD)) which can be 
easily collected in clinical setting.  A simple version of this equation has a clinical-friendly 
algorithm produces a score ranging from 0 to 10.5.  A score < 2.0 is deemed as having low risk 
of AVF primary failure, 2 - 3, moderate risk, 3.1- 7.9, high risk, and > 8, very high risk. However, 
this equation was not especially developed from or for older patients. Applying it to the U.S. 
older dialysis patients provides valuable information. The objective of this study is to validate 





Validation Data Set 
Our primary data source was derived from the 2010-2013 United States Renal Data 
System (USRDS) standard analytic files (SAFs).  We assembled our validation data set by 
extracting end stage renal disease (ESRD) patients aged 67 years and older who initiated 
hemodialysis with a CVC without a maturing AVF or AVG present between 7/1/2010 and 
6/30/2012 from Medical Evidence Form (Figure 1). Patients who did not have any Medicare 
inpatient or outpatient claim and those who had one or more vascular access placements (either 
AVF or AVG) in the two-year period prior to dialysis initiation were excluded. We further 
identified patients who had an AVF placement within 6 months of dialysis initiation by using 
CPT-4 codes of 36818, 36819, 36820, 36821, and 36825 from physician/supplier claims file. The 
final validation data set included 14,892 patients. 
 
Study Outcome 
The primary outcome of this study was AVF primary failure. We used the same 
definition of primary failure from Lok et al. - an AVF that was unable to be used for dialysis for 
a month within 6 months of its placement, despite interventions to facilitate its use – to define 
this outcome. It was ascertained as absence of vascular access modifier code ‘V7’ (AVF) from 
the institutional details claims file or absence of AVF with two needles reported from the 





AVF primary failure was expressed as a function of four binary variables in the Lok’s 
risk equation as: Logit (primary failure) = -2.0809 + 0.6907 x (age ≥ 65) + 0.9821 x (PVD) + 
0.8576 x (CAD) -1.0496 x (white).
9
 Lok et al. defined CAD as “coronary stenosis by 
angiography or history of myocardial infarction or previous coronary revascularization by 
angioplasty, stenting, or bypass surgery”. According to this definition, we determined a diagnosis 
of CAD by (1) myocardial infarction; (2) other forms of chronic ischemic heart disease including 
angina, coronary atherosclerosis and stenosis; and (3) coronary revascularization. To maximally 
capture patient’s existing diseases, we used one inpatient or outpatient diagnosis code (either 
primary or secondary) in the pre-ESRD institutional claims and physician/supplier claims 2 years 
prior to dialysis to ascertain PVD, CAD, and other comorbidities. Table S1 lists all diagnosis 
codes we used. We obtained patient’s age at dialysis initiation and race, primary cause of renal 
failure, pre-dialysis nephrology care patterns from Medical Evidence Form. Duration of CVC 
dependency was calculated as time from dialysis initiation to AVF placement. 
 
Statistical Analysis 
Patient characteristics and practice patterns were summarized in total. We calculated the 
predicted probabilities of AVF primary failure for each patient based on the Lok’s risk equation 
and assigned each patient into a risk category accordingly: high risk if the predicted value is ≥ 
40%; intermediate if 20 - 40%; and low  if < 20%. We assessed the external validity of the Lok’s 
model in older patients by applying it in the validation data set with the original regression 
coefficients. The discriminatory accuracy of the Lok’s model was evaluated by C-statistics, also 
known as the area under the receiver-operating characteristic curve (AUC). The value of C-
statistics corresponds to the probability that a randomly selected patient with the risk factors has 
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a higher predicted risk of AVF primary failure than a randomly selected patient without the risk 
factors.
10,11
 A value of 1.0 indicates that the score assigned by the model perfectly discriminates 
patients with different outcomes, while a value of 0.5 indicates that the scoring model contains 
no predictive information. Generally, models with a C-statistic greater than 0.70 are considered 
to have good discriminative ability and those greater than 0.80 are excellent. We used patient’s 
age at dialysis initiation, race, and the diagnosis of PVD and CAD within two years prior to 
dialysis to calculate the expected probability of AVF primary failure for each patient. Calibration 
of the model was examined by comparing the agreement between the predicted probabilities and 







The validation data set was comprised of 14,892 U.S. patients aged 67 years or older who 
initiated hemodialysis with a CVC and had a subsequent AVF placement. Table 1 presented 
patient demographics, comorbid conditions, and quality of care in the study cohort. The mean 
age of the patient population was 76.7 years old with 54.5 % of male and 76.0 % of White.  The 
population carried heavy disease burdens: 68.7% of them had diabetes, 86.2% had hypertension, 
64.0% had CAD, and 52.7% had PVD. The mean time from dialysis initiation to AVF placement 





Observed and Predicted Probability of AVF Primary Failure 
Among 14,892 patients, 7,374 (49.5%) had AVF primary failure within 6 months of AVF 
placement (Table 1). Patients who experienced AVF primary failure were more likely to be 
female and black race. Compared with those with matured AVFs, they carried more comorbid 
burdens (diabetes 42.7% vs. 41.1%; myocardial infarction 26.4% vs. 22.9%; history of stroke 
13.0% vs. 11.0%) and had less pre-dialysis nephrology care (no nephrology care 46.3% vs. 
45.0%).  The number and percentage of patients in each risk category of predicted probabilities 
of AVF primary failure were listed in Table 2. A total of 7.7% patients were considered as 
having high risk of primary failure. Their predicted probability and observed frequency of AVF 
primary failure was 0.61 and 0.53, respectively. A total of 40.5% of patients were in the 
intermediate category and 51.7% were in the low risk category. The predicted risk of AVF 
primary failure among patients in the intermediate category ranged from 0.35 to 0.40 and their 
observed proportion of primary failure was from 0.51 to 0.57. Approximately 45-48% of patients 
who were assigned to the low risk group experienced an AVF primary failure. Their predicted 
probability ranged from 0.08 to 0.20.  
 
Model Discrimination and Calibration 
When the Lok’s risk equation was applied to the validation data set, the C-statistics of the 
Lok’s risk equation was 0.53 (95% CI:  0.52-0.54) (Figure 2).  Figure 3 revealed the predicted 
probabilities of AVF primary failure corresponded poorly with the observed proportions in the 
calibration plot. Although the predicted risk of AVF primary failure differed significantly in each 
risk category, the observed frequencies of primary failure were similar. The observed frequency 
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of AVF primary failure in patients who had the highest predicted risk (0.61) was 0.53. The 




Our validation study shows the Lok’s risk equation for AVF primary failure performs 
poorly when externally applied to a national cohort of incident hemodialysis patients aged 67 
years or older. The model exhibits a very low discriminative ability which nearly provides no 
predictive information. Calibration plot demonstrates the predicted probabilities correspond 
poorly with the observed percentages of AVF primary failure. The decrease in predicted 
accuracy is of such a degree that the model appears useless for clinical decision-making of 
vascular access choice in older hemodialysis patients.  
Our finding that the Lok’s model for AVF primary failure has low predicted accuracy 
when externally validated in the US older hemodialysis patients is consistent with the findings 
from Lilly et al.
13
 They used the Lok’s classification system to calculate risk scores for AVF 
primary failure in all U.S. adult patients at their first hemodialysis session from 2005 to 2009. 
Although they reported predicted probability of AVF primary failure was inversely associated 
with percentages of AVF maturation, the effect was small. Rate of AVF maturation varied from 
19.0% in patients in the “very high” predicted risk category to 25.6% in patients in the “low” risk 
one. The odds of AVF primary failure were lower in adult patients from the moderate-, high-, 
and very high-risk categories than those in low-risk categories with odds ratio of 0.90, 0.80, and 
0.68, respectively.  
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Various aspects need to be considered to address these results. Firstly, our validation data 
set is considerably larger and more diverse than the cohort in Lok’s study. The Lok’s risk 
equation was developed from a prospective cohort of 422 patients from a university-based health 
care program in Canada. Our validation cohort was a population of 14,892 U.S. older 
hemodialysis patients from nationwide dialysis facilities. The Lok’s cohort included more males 
(67.8%). It was younger (mean age of 58) and healthier (diabetic 28.4%, hypertension 76%, 
CAD 32.2%, and PVD 8.3%) than our cohort (diabetic 68.8%, hypertension 86.3%, CAD 64.1%, 
and PVD 52.8%). More importantly, practice patterns of AVF placement have been changed 
dramatically since the Lok’s study was published. In the study by Lok et al., AVFs were created 
between 1995 and 2004, while AVFs were created from 2010 to 2012 in our study. In 2003, the 
Centers for Medicare and Medicaid Service (CMS) launched the Fistula First Breakthrough 
Initiative (FFBI). In collaboration with the 18 national ESRD Networks, CMS promulgated the 
FFBI goal of achieving functional AVF use in greater than 65% of hemodialysis patients through 
its Clinical Performance Measures (CPMs) and established Quality Improvement and Patient 
safety (QIPS) rules.
14
 After “Fistula First” campaign, dialysis facilities are inclined to assign 
more patients to AVF creation. Patients who are the suitable candidates for AVG creation, for 
example, those who have inferior vasculature, were more likely to be referred to AVF placement 
after “Fistula First”.  This practice increases the likelihood of AVF primary failure. The high rate 
of AVF primary failure in our cohort (49.2% versus 14% and 39% in the Lok’s study, 
respectively, in the training and validation data set) can only be explained partly by advanced age 
and comorbid conditions, whereas change in clinical practice pattern is the major reason.  
We expect a complex prediction model which incorporates additional variables relevant 
to AVF maturation increases prediction ability. For example, gender was not included in the 
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Lok’s model because it was only borderline significant in their training data and was not 
statistically significant in the internal cross-validation.
9
 In our data set, however, gender is 
significantly associated with AVF primary failure, as aligned with other studies on risk factors 
for AVF primary failure.
15, 16, 17
 In Lily’s study, several factors that dropped out the Lok’s model 
were highly significantly including diabetes, hypertension, congestive heart primary failure, 
other cardiac disease, cerebrovascular disease, gender, Hispanic ethnicity, BMI, prior 
nephrologist care, insurance, and year maintenance hemodialysis started. Adding these variables 
in the prediction model probably improves the predictive accuracy for AVF maturation. It is also 
highly possible that the poor vascular access outcome is not only the results of patient 
demographics, comorbid conditions, and clinical care patterns, but other factors (e.g. AVF 
location, arterial diameter,
18
 and vein diameter
19
). Feldman et al
 
developed a prediction model 
for AVF maturation based on a cohort of 348 adult patients from 12 hospitals in the Delaware 
Valley Region.
20
 The C-statistics for internal validation was 0.66 for the model including 
patient’s age, diagnosis of cardiovascular disease, previous access history, mean arterial pressure 
<85 mm Hg, and dialysis dependency. After adding in heparin use and upstream vein diameter, 
the C-statistics was improved to 0.69.   Robbin et al. recently established a prediction model for 
AVF unassisted and overall maturation based on data from Hemodialysis Fistula Maturation 
(HFM) Study which is a prospective, multi-center cohort study with 602 enrolled patients.
21
 
Their model only included three post-operative ultrasound parameters (AVF blood flow, 
diameter, and depth) but it exhibited strong predict ability. The C-statistics of their model was 
0.69, 0.74, and 0.79, respectively, for unassisted maturation, and 0.69, 0.71, and 0.76, 
respectively, for overall AVF maturation at 1 day and 2 and 6 weeks after AVF placement. 
However, some predictors including vein and artery parameters in last two models are not 
113 
 
routinely collected in the USRDS data; it is impossible to validate them in this study to derive a 
useful clinical decision tool for AVF placement.  
Despite its clear findings and the large national population used, our study has several 
limitations. First, we relied on AVF modifier codes or types of access used on the reported 
dialysis session to ascertain AVF maturation and patency. Access type reported from the dialysis 
claim may not reflect the AVF most frequently used for dialysis in the month. These codes were 
submitted by dialysis facilities for billing purpose and thus likely to be subjected to 




haven’t been validated. Secondly, the diagnosis of PVD and CAD and other comorbidities 




In conclusion, using a national cohort of older patients who initiated hemodialysis with a 
CVC and had a subsequent, incident AVF placement, we have externally validated the Lok’s risk 
equation for AVF primary failure. We found the Lok’s model had inadequate discrimination or 
calibration ability to predict AVF primary failure in older hemodialysis patients. A more 
complex model with strong predictors for AVF primary failure is expected to better serve clinical 
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Table 1. Baseline characteristics of the validation data set of older patients who initiated 








Total cohort 14,892 
Demographics  
Age at dialysis initiation (yrs)(mean±SD) 76.7±6.5 
      67-<75 6,196(41.6) 
      75-<85 6,641(44.6) 
      ≥85 2,055(13.8) 
Gender  
      Male 8,115(54.5) 
      Female 6,777(45.5) 
Race  
      White 11,322(76.0) 
      Black 2,755(18.5) 
      Other/unknown 815(5.5) 
Comorbid conditions  
Primary cause of renal failure  
      Hypertension/Large vessel disease 5,453(36.6) 
      Diabetes 6,236(41.9) 
      Glomerulonephritis 527(3.5) 
      Other 2,676(18.0) 
Diabetes 10,235(68.7) 
Hypertension 12,839(86.2) 
Coronary artery disease 9,533(64.0) 
      Myocardial infarction 3,665(24.6) 
      Atherosclerosis 9,227(62.0) 
      Coronary revascularization 854(5.7) 
Congestive heart failure 10,463(70.3) 
Peripheral vascular disease 7,848(52.7) 
Cerebrovascular disease 4,670(31.4) 
History of stroke 1,785(12) 
Chronic obstructive pulmonary disease 5,757(38.7) 
Cancer 2,968(19.9) 
Care patterns  
CVC dependency (days, mean ± SD) 70.8±42.5 
Nephrology care  
      No care 6,799(45.7) 
      0-6 months 2,311(15.5) 
      6-12 months 2,393(16.1) 








Table 2. Observed probability and risk category of arteriovenous fistula (AVF) primary failure 















Risk category N(%) PVD CAD White Predicted 
probability of 




High (≥40%) 1,152(7.7) 1,152(7.7) Yes Yes No 0.61 0.53 
Intermediate 
(20%-<40%) 
6,038(40.5) 516(3.5) Yes No No 0.40 0.57 
869(5.8) No Yes No 0.37 0.51 
4,653(31.2) Yes Yes Yes 0.35 0.52 
Low 
(<20%) 
7,702(51.7) 1,033(6.9) No No No 0.20 0.48 
1,527(10.3) Yes No Yes 0.19 0.47 
2,859(19.2) No Yes Yes 0.17 0.49 
2,283(15.3) No No Yes 0.08 0.45 















Fistula or graft was the initial 
vascular access for dialysis 
(n=34,967) 
Did not have a Medicare claim 
2 years prior to dialysis 
initiation 
(n=10,373) 
57,137 used catheter to initiate dialysis without 
other vascular access 
46,764 had at least one Medicare claim 2 years 
prior to dialysis initiation 
 
43,851 had no prior fistula or graft placement 
using 2 years of pre-ESRD claims 




Age < 67 years old  
(n=109,205) 
Had fistula or graft placement 
in 2 years prior to dialysis 
initiation (n=2,913) 
Did not receive a fistula 
placement within 6 months 
(n=29,963) 
92,104 aged 67 or older at dialysis initiation 








Figure 2. Receiver operating characteristics (ROC) curves showing the discriminative accuracy 
of the Lok’s risk equation in U.S. older patients who initiated hemodialysis with a catheter and 
had subsequent arteriovenous fistula (AVF) placement. The dash line: the Lok’s risk equation 
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Figure 3. Calibration plot of predicted risk of arteriovenous fistula (AVF) primary failure by the 
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Table S1. International Classification of Diseases (ICD-9) and Healthcare Common Procedure Coding System (HCPCS) codes used 








Co-Morbid Events Prior to ESRD ICD-9 Codes HCPCS Codes 
Diabetes 250,357.2,362.0,366.41  
Hypertension 401  
Coronary Artery Disease   
     Myocardial Infarction 410,412  
     Atherosclerosis/stenosis 413,414  
     Coronary Revascularization 360,361, 00.66,v4581,v4582 9298x,3351x,3352x,92990-92996,33531-33536 
Congestive Heart Failure 398.91,402.01,402.11,402.91,404.01,404.03,404.11,404.13,404.91,404.93,42
5.4-425.9,428 
 
Peripheral Vascular Disease  440-444,447,451-453,557  
Cerebrovascular Disease 362.34, 430-438  
Stroke 430,431,436,433x1,434x1  
Chronic Obstructive Pulmonary Disease  491.0,491.1,491.8,491.9,491.20,491.21,491.22,492.0,492.8,494.0,494.1,496  









SELECTING IMPORTANT PREDICTORS FOR ARTERIOVENOUS 
FISTULA MATURATION IN OLDER HEMODIALYSIS PATIENTS BY 






Background: Placing an arteriovenous fistula (AVF) in older hemodialysis patients at great risk 
of AVF primary failure leads to prolonged dependency on central venous catheter (CVC) and 
associated inferior patient outcomes. A model which accurately predicts AVF maturation can 
facilitate better clinical determination for AVF placement in older hemodialysis patients. 
Methods: We assembled a retrospective cohort of 14,892 patients aged 67 years and older who 
started hemodialysis with a CVC between 7/1/2010 and 6/30/2012 and had a subsequent, 
incident AVF placement from the United States Renal Data System (USRDS). We randomly 
divided the study cohort into training (9,829, 66%) and validation data sets (5,063, 34%) and 
used random survival forests (RSF) with competing risks to identify important predictors for 
AVF maturation. Results: A total of 49.7% patients in the training data set achieved AVF 
maturation and 13.6% had a competing event. The median time to maturation was 4 (IQR: 3-5) 
months. From the RSF of 1,000 trees based on 34 variables, patient’s gender had the highest 
variable importance (VIMP, 0.0027), followed by race, being institutionalized, days on 
hemodialysis without an AVF, estimated glomerular filtration rate, and body mass index with 
borderline importance (VIMP ≥ 0.0005). The out-of-bag (OOB) error rate of the RSF was 45.3% 
and 45.8% for AVF maturation in the training and validation data sets, respectively. Conclusions: 
Predictors captured in USRDS data have limited ability to predict AVF maturation. Among the 
available predictors, patient’s gender might be considered as the most important predictor for 





Clinical guidelines recommend matured arteriovenous fistula (AVF) as the optimal type 
of vascular access for hemodialysis patients of all ages. In older dialysis recipients, AVF, once 
matured, is associated with long-term benefits of greater patency and requires less interventional 
procedures to maintain functionality as compared to another type of permanent vascular access, 
arteriovenous graft (AVG).
1
 Studies, however, show increased age is associated with reduced 
rate of AVF maturation. Nationwide, the prevalence of AVF maturation was lower in patients 
over 75 years (61%) as compared to those 65-74 (64%) and 45-64 (67%).
2
 In the meta-analysis 
of AVF outcomes from 10 studies which defined elderly from >50 to >70 years old, the rate of 
AVF primary failure was significantly higher in elderly compared with that in nonelderly.
3
 A 
model which accurately predicts AVF maturation in older hemodialysis patients based upon 
patient characteristics, comorbid conditions, and life expectancy can facilitate better clinical 
decision making for vascular access choice. To date, there were few existing models to predict 
AVF maturation especially developed for older dialysis recipients. Lok et al. established a 
scoring system to estimate the risk of failure of AVF maturation based on 422 Canadian adult 
hemodialysis patients with a first-time AVF placement.
4
 This model incorporates four patient-
level predictors including patient age, race, diagnosis of peripheral vascular disease and coronary 
artery disease and achieved a good predictive accuracy.  Feldman et al. derived another model 
from a cohort of 348 U.S. adult hemodialysis patients from the Delaware Valley Region.  In 
additional to patient’s age and history of cardiovascular disease, their model included history of 
previous vascular access, mean arterial pressure, dialysis dependency, heparin use, and vein 
diameter to predict AVF maturation.
5
  Both models, however, were developed a decade ago from 
regional studies for all adult patients. The aim of this study is to identify important predictors for 
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AVF maturation for older adults receiving hemodialysis. Developing a clinically friendly model 







Our primary data source was derived from the 2010-2013 United States Renal Data 
System (USRDS) standard analytic files (SAFs).  We assembled our validation data set by 
extracting patients aged 67 years and older who initiated hemodialysis with a CVC without a 
maturing AVF or AVG present between 7/1/2010 and 6/30/2012 from Medical Evidence Form 
(Figure 1). Patients who did not have any Medicare inpatient or outpatient claim and those who 
had one or more vascular access placements (either AVF or AVG) in the two-year period prior to 
dialysis initiation were excluded. We further identified patients who had an AVF placement 
within 6 months of dialysis initiation by using CPT-4 codes of 36818, 36819, 36820, 36821, and 
36825 from physician/supplier claims file. The final validation data set included 14,892 patients. 
 
Study Outcome and Competing Events 
The primary outcome of this study was AVF maturation. It was defined as an AVF can 
be used with two-needle cannulation for two-thirds or more of all prescribed dialysis for one 
month. We ascertained AVF maturation as presence of vascular access modifier code ‘V7’ (AVF) 
from the institutional details claims file or presence of AVF with two needles reported from the 
Crownweb clinical file. Patients who died, switched to peritoneal dialysis, or received a kidney 
transplant without evidence of AVF maturation were treated as experiencing competing events.  
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They were identified by using the death file, transplant file and dialysis institutional claims file, 
respectively. Patients were followed from the date of AVF placement to AVF maturation, 
competing events, or 6 months after AVF placement, whichever came first.  
 
Study Predictors 
We selected 34 candidate predictors based on the existing literature of AVF maturation 
and their availability in the USRDS data. From the Medical Evidence Form, the following 
potential risk factors were extracted at dialysis initiation: patient demographics (age, gender, and 
race), residential region (New England, Mid-Atlantic, West, Southwest, Midwest, and South), 
functional status (amputation, inability to ambulate or transfer, needs assistance with daily 
activities, and being institutionalized), lab values (body mass index (BMI), hemoglobin, serum 
albumin, and estimated glomerular filtration rate (eGFR)), primary cause of renal failure 
(hypertension/large vessel disease, diabetes, glomerulonephritis, or other), pre-dialysis 
nephrology care patterns (no care, 0-6 months, 6-12 months, and >12 months). To maximally 
capture patient’s existing diseases, we used one inpatient or outpatient diagnosis code (either 
primary or secondary) in the pre-end stage renal disease (ESRD) institutional claims and 
physician/supplier claims 2 years prior to dialysis to score their comorbid conditions. The major 
comorbid conditions included were diabetes, hypertension, coronary artery disease (myocardial 
infarction, atherosclerosis, and coronary revascularization), congestive heart failure, peripheral 
vascular disease, cerebrovascular disease, dyslipidemia, stroke, chronic obstructive pulmonary 
disease, cancer, depression, and dementia. Smoking status was also ascertained from the pre-
dialysis claims file. ESRD network number, facility profit status and hospital association were 
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ascertained from the facility file. Days on hemodialysis without an AVF were calculated as time 
from dialysis initiation to AVF placement.  
 
Statistical Analysis 
Derivation and Validation Data sets 
We randomly divided the study cohort into two non-overlapping subcohorts-a training 
data set (9,829, 66%) and a validation data set (5,063, 34%). Baseline patient characteristics and 
practice patterns were presented, with continuous variables expressed as mean ± SD and 
categorical variables as frequencies.  
 
Forests Analysis 
We used random survival forests (RSF) with competing risks to select predictors for AVF 
maturation. RSF is an ensemble tree method for the analysis of right censored survival data.
6
 
Using the training data set, we constructed a RSF based on 1,000 bootstrap samples. Each tree 
was built from an independent and unique bootstrap sample (Figure 2). Each time when a RSF 
was build, 1/3 of data were automatically excluded as out-of-bag (OOB) data for validation. At 
each tree node, we randomly selected a set of variables. The number of variables selected was 
the square root of the total number of all potential predictors. The variable which had the highest 
log-rank value was selected to be the best splitting variable. It was used to split the node into two 
branches. Branches were continued to split until the terminal branches had no fewer than 3 
outcomes. The randomness was introduced by both bootstrap sampling of patients from the 
original cohort and random sampling of variables at each tree node. We also plotted the 
ensemble cumulative incidence function (CIF) and the cause-specific cumulative hazard function 
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(CSCHF), which refers to the sum of the hazard function across all the different survival times in 
the data set. Statistical analyses were performed using SAS (version 9.3; SAS institute, Cary, NC) 





Validation of the Prediction Model 
Predictive accuracy of the predict model developed from the grown RSF was assessed by 
the average prediction error calculated both internally using the OOB data and the validation data 
set. Prediction error is 1 minus Harrell’s C statistic (C index). A value of 1 for Harrell’s C-
statistic corresponds to perfect prediction, while a value of 0.5 indicates prediction does not 
perform better than random guessing.  
 
Identification of Predictive Variables 
The importance of each variable was determined by Brieman-Cutler permutation variable 
importance, referred as VIMP. VIMP measures change in prediction error average over all trees 
for a RSF grown with and without a variable. A positive value for VIMP indicates that prediction 
error increase without the variable and that the variable is predictive. The larger the VIMP, the 
more predictive the variable is. We used VIMP ≥ 0.0005 as a threshold to identify important 





Missing Data Imputation 
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Preliminary exploration of the data showed missing of serum albumin (26.3%), BMI 
(0.6%), hemoglobin (8.5%), eGFR (3.2%), facility profit status (0.3%), and facility hospital 
association (0.3%) at baseline did not follow the pattern of missing completely at random 
(MCAR). Missing of lab values depended on comorbidity index, BMI, and age at dialysis 
initiation. It is also possible that the lab values in the normal range were less likely to be reported, 
so the missing mechanism could be missing not at random (MNAR). We used the RSF 
embedded method which imputes missing values of the selected variables at the node by random 





We tested the robustness of the prediction ability of these risk factors by two additional 
analyses.  From the first RSF with all 34 potential predictors, we built two subsequent RSFs after 
removing noise variables with VIMP ≤  0. We checked the consistency of the ranking and 
relative size of VIMP in these two RSFs. We also repeated our analyses by reconstructing a RSF 
after excluding observations with missing values. This complete-case analysis allowed us to 





Table 1 presented patient demographics, comorbid conditions, limited functional status, 
lab values, and quality of care in the study cohort. The mean age of the patient population was 
76.7±6.5 years old with 54.5% of male and 76.0% of White.  The population carried heavy 
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disease burdens: 68.7% of them had diabetes, 86.2% were hypertensive, 64.0% had coronary 
artery disease, and 17.1% needed assistance for daily activities. The mean time from dialysis 
initiation to AVF placement was 70.8±42.5 days and 45.7% of patients started dialysis without 
any pre-dialysis nephrology care.  
 
AVF Maturation 
Out of 14,892 patients, 50.5% achieved AVF maturation, 12.9% had a competing event, 
and the remaining 36.6% dialyzed without a useable AVF 6 months after AVF placement (Table 
1). Among patients whose achieved AVF maturation, the median time to maturation was 4 (IQR: 
3-5) months. AVF maturation was more likely to occur in patients who were male, younger than 
85 years old, and non-black race. Compared to patients who had a failed AVF or a competing 
event, they were slightly healthier (diabetes: 66.9% vs. 71.9% or 66.9%; hypertension: 85.6% vs. 
86.7% or 87.3%; coronary artery disease: 62.4% vs. 62.9% or 73.5%), had better functional 
status (need assistance with daily activities: 15.1% vs. 18.1% or 22.4%, being institutionalized: 
10.1% vs. 13.1% or 18.7%),  and had pre-dialysis nephrology care (no nephrology care: 45.0% 
vs. 46.3% or 46.4%). 
 
RSF Analysis 
A total of 49.7% out of 4,882 patients in the training data set achieved AVF maturation, 
13.6% had competing events, and 36.7% remained dialyzing with a CVC within 6 months after 
AVF placement. The OOB error rate of the RSF was 45.3% for AVF maturation and 40.4% for 
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competing events, respectively (Table 2). From the RSF of 1,000 trees based on 34 variables, 
gender was the most predictive variable (VIMP, 0.0027), followed by race, being 
institutionalized, eGFR, BMI, days on dialysis without an AVF, atherosclerosis, and dialysis 
network by decreasing order of importance (VIMP ≥ 0.0005) (Table 3). Except gender, all the 
other variables had smaller VIMP. Variables which did not provide predictive information were: 
hemoglobin, coronary revascularization, smoke, hypertension, inability to transfer, 
cerebrovascular disease, and amputation. Figure 3 showed the ensemble cumulative incidence 
function (CIF) and cause-specific cumulative hazard function (CSCHF) in the period of 6 
months. AVF maturation increased slowly in the first 2 months after placement; however, it 
accelerated from 2-6 months. 
 
Sensitivity Analyses 
After removing 7 variables of which the VIMP ≤ 0 including hemoglobin, coronary 
revascularization, smoke, hypertensions, inability to transfer, cerebrovascular disease and 
amputation, we built the second RSF with 1,000 bootstrap samples based on 27 potential 
predictors. Gender, race, being institutionalized, GFR, BMI, and days on dialysis without an 
AVF remained predictive with VIMP ≥ 0.0005 (Table S1A). Atherosclerosis and dialysis 
network, however, were no longer identified as important predictors. The third RSF was built 
based on 22 variables after further removing 5 variables with VIMP ≤ 0 including stroke, age at 
dialysis initiation, chronic obstructive pulmonary disease, nephrology care, and cancer. It 
showed the predictors identified with VIMP ≥ 0.0005 from the first RSF including gender, race, 
being institutionalized, GFR, and BMI still had higher VIMP than other predictors (Table S1B). 
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Days on dialysis without an AVF did not appear as a major predictor any more. In both second 
and third RSF, gender, race, being institutionalized, eGFR, and BMI were qualified as important 
predictors for AVF maturation above the prerequisite threshold.  There was an increasing trend 
of VIMP with reduced number of predictors, however, the OOB error rate was not significantly 
improved (from 45.3% to 45.2% and 44.3%, respectively, for the RSFs with 34, 27, and 22 
variables) (Table 2 and Table S2).  
After excluding 4,658 records with missing values, we randomly divided 10,234 
observations into a training (6,798) and a testing data set (3,436). A new RSF was built based 34 
potential predictors. Among 6,798 patients, 3,411 (50.2%) of them had an AVF matured and 908 
(13.4%) had competing events. The OOB error rate was 45.2% for AVF maturation and 41.8% 
for competing events, respectively. When applied to the validation data set, the OOB error rate 
was 45.4% for AVF maturation and 58.5% for competing events (Table S3). Gender, race, 
facility profit status, BMI, myocardial infarction, GFR, days on dialysis without an AVF, serum 
albumin, diabetes, and age at dialysis initiation appeared to have VIMP ≥ 0.0005 (Table S4).  
 
DISCUSSION 
Using a large national cohort of older hemodialysis patients with a newly created AVF, 
we identify patient’s gender as the important predictor for AVF maturation. Race, being 
institutionalized, eGFR, BMI, and days on hemodialysis without an AVF provide borderline 
predictive information. However, predictors captured in USRDS data have limited ability to 
predict AVF maturation.  
Gender as an independent risk factor for AVF surgery and maturation has been well 
documented in previous studies. Allon et al examined factors associated with AVF prevalence in 
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1,824 patients in the multicenter Hemodialysis (HEMO) Study.
8
 They reported gender was the 
most significant risk factor among all investigated demographic and clinical factors including 
age, gender, race, BMI, income, education, diabetes, hypertension, coronary artery disease, 
congestive heart failure, and peripheral vascular disease. Similarly, Peterson et al showed gender 
was associated with the larger negative effect on AVF maturation as compared to age and AVF 
location in a group of 205 hemodialysis patients selected by preoperative vascular mapping.
9
 In a 
USRDS study of 9,458 incident hemodialysis patients aged 67 years and older who initiated 
dialysis between 2010 and 2011, 44% of females received an AVF as compared to 56% of 
males.
10
 Among patients who had an AVF placed, 57% of females had AVF maturation failure 
and 47% needed one or more interventional procedure to assist maturation as compared to 47% 
and 40% in males, respectively. The same study also showed gender was associated with higher 
likelihood of inferior AVF outcomes after maturation. A larger proportion of matured AVF was 
abandoned in females (21%) than in males (16%). The discrepancy in AVF placement, 
maturation, assisted maturation, and abandonment persisted after adjusting for age, race, stroke, 
coronary artery disease, and comorbid score. In addition, our study shows following gender, 
patient’s race and BMI repeatedly present as two predictors with relatively high importance. All 
three variables might be viewed as proxies for vessel size and configuration. 
However, our study indicates that the USRDS data does not include strong variables to 
predict AVF maturation.  This is proved by the very low predictive ability of the models 
developed by all RSF in this study. Although USRDS routinely collects extensive data on patient 
clinical and comorbid information, it does not inform on predictors such as arterial and venous 
vessel size and blood flow from preoperative ultrasound evaluation. As indicated by a recent 
publication from the Hemodialysis Fistula Maturation (HFM) Study, which was a prospective, 
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multicenter cohort study examining the association of ultrasound parameters with AVF 
maturation, three post-operative ultrasound parameters exhibited strong predictive ability for 
AVF maturation. A prediction model including AVF blood flow, diameter, and depth at 1 day 
and 2 and 6 weeks after AVF placement achieved C statistics of 0.69, 0.74, and 0.79, 
respectively for unassisted maturation and 0.69, 0.71, and 0.76, respectively, for overall AVF 
maturation.
 
Patient’s case-mix factors including age, gender, race, dialysis status, diabetes, BMI 
and AVF location (forearm versus upper arm) were not associated with unassisted or overall 
AVF maturation.
11
 We highly recommend future studies further evaluate these parameters for 
possibilities to include ultrasound evaluation as a routine clinical practice.  
There are several advantages to using RSF. As an extension of random forests, RSF is a 
highly used machine learning method that gradually gained much popularity in the field of 
epidemiology.
12,13
 Different from traditional statistical methods such as Cox proportional hazards 
model which has to reply on proportional hazards assumption, RSF does not depend on any 
distribution assumption and can accommodate non-linear effects or higher order interactions for 
predictors.   
Certain weakness in this study should be noted. First and foremost, the USRDS data does 
not contain strong predictors which can be linked to biological processes of maturation. When a 
covariate for maturation is absent in the data, RSF can miss it as an important predictor. 
Secondly, our study only includes older patients (≥ 67 years), and may not generalize to younger 
dialysis patients. Thirdly, we are unable to validate the model developed in an external 





  In conclusion, the USRDS data may not include the strong predictors and has limited 
ability to predict AVF maturation. Among the available predictors, patient’s gender might be 
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Table 1. Baseline characteristics of older patients who initiated hemodialysis with a catheter and 




 Total AVF matured No event Died/TX/PD 
Total cohort 14,892 7,518(50.5) 5,453(36.6) 1,921(12.9) 
Demographics     
Age at dialysis initiation (yrs)(mean±SD) 76.7±6.5 76.6±6.4 76.5±6.4 77.7±6.7 
      67-<75 6,196(41.6) 3,155(42.0) 2,344(43.0) 697(36.3) 
      75-<85 6,641(44.6) 3,367(44.8) 2,393(43.9) 881(45.9) 
      ≥85 2,055(13.8) 996(13.3) 716(13.1) 343(17.9) 
Gender     
      Male 8,115(54.5) 4,515(60.1) 2,508(46.0) 1,092(56.9) 
      Female 6,777(45.5) 3,003(39.9) 2,945(54.0) 829(43.2) 
Race     
      White 11,322(76.0) 5,788(77.0) 3,910(71.7) 1,624(84.5) 
      Black 2,755(18.5) 1,270(16.9) 1,243(22.8) 242(12.6) 
      Other/unknown 815(5.5) 460(6.1) 3,00(5.5) 55(2.9) 
Comorbid conditions     
Primary cause of renal failure     
      Hypertension/Large vessel disease 5,453(36.6) 2,756(36.7) 1,955(35.9) 742(38.6) 
      Diabetes 6,236(41.9) 3,090(41.1) 2,445(44.8) 701(36.5) 
      Glomerulonephritis 527(3.5) 309(4.1) 161(3.0) 57(3.0) 
      Other 2,676(18.0) 1,363(18.1) 892(16.4) 421(21.9) 
Diabetes 10,235(68.7) 5,028(66.9) 3,921(71.9) 1,286(66.9) 
Hypertension 12,839(86.2) 6,433(85.6) 4,730(86.7) 1,676(87.3) 
Coronary artery disease 9,533(64.0) 4,694(62.4) 3,428(62.9) 1,411(73.5) 
      Myocardial infarction 3,665(24.6) 1,719(22.9) 1,319(24.2) 627(32.6) 
      Atherosclerosis 9,227(62.0) 4,543(60.4) 3,312(60.7) 1,372(71.4) 
      Coronary revascularization 854(5.7) 424(5.6) 299(5.5) 131(6.8) 
Congestive heart failure 10,463(70.3) 5,094(67.8) 3,839(70.4) 1,530(79.7) 
Peripheral vascular disease 7,848(52.7) 3,830(50.9) 2,871(52.7) 1,147(59.7) 
Cerebrovascular disease 4,670(31.4) 2,294(30.5) 1,747(32.0) 629(32.7) 
Dyslipidemia 10,823(72.7) 5,455(72.6) 3,957(72.6) 1,411(73.5) 
Stroke 1,785(12.0) 827(11.0) 696(12.8) 262(13.6) 
Chronic obstructive pulmonary disease 5,757(38.7) 2,750(36.6) 2,081(38.2) 926(48.2) 
Cancer 2,968(19.9) 1,517(20.2) 1,011(18.5) 440(22.9) 
Depression 2,437(16.4) 1,135(15.1) 956(17.5) 346(18.0) 
Dementia 995(6.7) 462(6.2) 387(7.1) 146(7.6) 
Smoke 1,431(9.6) 725(9.6) 518(9.5) 188(9.8) 
Limited functional status     
Amputation 191(1.3) 98(1.3) 61(1.1) 32(1.7) 
Inability to ambulate 1,239(8.3) 499(6.6) 499(9.2) 241(12.6) 
Inability to transfer 616(4.1) 238(3.2) 257(4.7) 121(6.3) 
Needs assistance with daily activities 2,552(17.1) 1,133(15.1) 988(18.1) 431(22.4) 
Being institutionalized 1,835(12.3) 759(10.1) 716(13.1) 360(18.7) 
Lab values     
Body mass index (kg/m2)(mean±SD) 28.5±7.3 28.2±7.0 28.9±7.5 28.1±7.4 
Hemoglobin (g/dl, mean ± SD) 10±13.6 10.2±18.9 9.8±2.4 10±3.3 
Serum albumin (g/dl, mean ± SD) 3.2±5.5 3.3±6.4 3.1±0.8 3.4±8.4 
GFR (ml/min/1.73 m2,  mean ± SD) 13.1±5.6 12.8±5.5 13.1±5.6 14.3±5.8 
Care patterns     
Duration of CVC dependency  (days, mean ± SD) 70.8±42.5 69.7±41.7 72.7±43.7 69.8±42 
Nephrology care     






      0-6 months 2,311(15.5) 1,184(15.8) 815(15.0) 312(16.2) 
      6-12 months 2,393(16.1) 1,231(16.4) 854(15.7) 308(16.0) 
     12 months 3,389(22.8) 1,720(22.9) 1,259(23.1) 410(21.3) 
Facility type     
     Hospital-based 1,320(8.9) 733(9.8) 445(8.2) 142(7.4) 
     Freestanding 13,532(91.1) 6767(90.2) 4,991(91.8) 1,774(92.6) 
Profit status     
     For-profit 12,460(83.9) 6,153(82.0) 4,653(85.6) 1,654(86.3) 
     Non-profit 2,316(15.6) 1,310(17.5) 749(13.8) 257(13.4) 
     Unknown 76(0.5) 37(0.5) 34(0.6) 5(0.3) 







Table 2. Summary output from Random Survival Forests (RSF) analysis based on 34 potential 





 Training Testing 
Sample size 9,829 5,063 
Number of events 4,882 and 1,340 2,636 and 581 
Number of trees 1,000 1,000 
Number of variables tried at each split 6 6 
Total number of variables 34 34 
OOB error rate for AVF maturation 45.3% 45.8% 







Table 3. Variable importance (VIMP) of 34 potential predictors for arteriovenous fistula (AVF) 
maturation and competing events from Random Survival Forests (RSF) analysis of 1,000 trees 







Potential predictors AVF maturation Competing events 
Gender 0.0027 -0.0003 
Race 0.0008 0.0028 
Being institutionalized 0.0007 0.0026 
Estimated glomerular filtration rate 0.0007 0.0028 
Body mass index 0.0007 0.0009 
Days on dialysis without an AVF 0.0007 0.0003 
Atherosclerosis 0.0006 0.0007 
Network 0.0005 0.0016 
Congestive heart failure 0.0004 0.0013 
Facility profit status 0.0004 0.0001 
Myocardial infarction 0.0004 0.0024 
Region 0.0004 0.0015 
Age at dialysis initiation 0.0003 0.0014 
Needs assistance with daily activities 0.0003 0.0003 
Primary cause of renal failure 0.0003 0.0009 
Peripheral vascular disease 0.0003 0.0001 
Cancer 0.0003 0.0003 
Depression 0.0003 0.0000 
Diabetes 0.0002 0.0002 
Serum albumin 0.0002 -0.0002 
Facility hospital association 0.0002 0.0000 
Nephrology care 0.0002 0.0001 
Dementia 0.0001 0.0001 
Chronic obstructive pulmonary disease 0.0001 0.0012 
Dyslipidemia 0.0001 -0.0003 
Inability to ambulate 0.0001 0.0004 
Stroke 0.0001 0.0002 
Amputation 0.0000 0.0000 
Cerebrovascular disease 0.0000 0.0003 
Inability to transfer 0.0000 0.0002 
Hypertension 0.0000 -0.0001 
Smoke -0.0001 -0.0001 
Coronary revascularization -0.0001 0.0001 











Fistula or graft was the initial 
vascular access for dialysis 
(n=34,967) 
Did not have a Medicare claim 
2 years prior to dialysis 
initiation 
(n=10,373) 
57,137 used catheter to initiate dialysis without 
other vascular access 
46,764 had at least one Medicare claim 2 years 
prior to dialysis initiation 
 
43,851 had no prior fistula or graft placement 
using 2 years of pre-ESRD claims 




Age < 67 years old  
(n=109,205) 
Had fistula or graft placement 
in 2 years prior to dialysis 
initiation (n=2,913) 
Did not receive a fistula 
placement within 6 months 
(n=29,963) 
92,104 aged 67 or older at dialysis initiation 








Figure 2. Example of a random tree. A bootstrap sample of patients from the original data set is 
used to create a random tree. At the root, a random set of variables is selected to be candidates, 
and the most predictive variable for survival among those is identified. Node levels are 
numbered based on their relative distance to the trunk of the tree. Splitting of nodes to create the 





Level 0 node 
Level 2 node 
Level 3 node 
Level 4 node 








Figure 3. The cause-specific cumulative hazard function (CSCHF) and ensemble cumulative 
incidence function (CIF) for arteriovenous fistula (AVF) maturation (black line) and competing 
events (red line) from a competing risk analysis in hemodialysis patients aged 67 and older. The 

















Table S1A. Variable importance (VIMP) of 27 potential predictors for arteriovenous fistula 
(AVF) maturation and competing events from Random Survival Forests (RSF) analysis of 1,000 





Potential predictors AVF maturation Competing events 
Gender 0.0029 0.0000 
Race 0.0009 0.0027 
Days on dialysis without an AVF 0.0007 0.0008 
Glomerular filtration rate 0.0006 0.0029 
Body mass index 0.0006 0.0007 
Being institutionalized 0.0006 0.0025 
Myocardial infarction 0.0005 0.0026 
Facility profit status 0.0005 -0.0001 
Peripheral vascular disease 0.0004 0.0002 
Region 0.0003 0.0016 
Congestive heart failure 0.0003 0.0010 
Diabetes 0.0003 0.0003 
Network 0.0003 0.0012 
Inability to ambulate 0.0003 0.0006 
Dyslipidemia 0.0002 -0.0002 
Atherosclerosis 0.0002 0.0007 
Dementia 0.0002 0.0001 
Depression 0.0002 -0.0001 
Facility hospital association 0.0001 0.0000 
Serum albumin 0.0001 -0.0001 
Primary cause of renal failure 0.0001 0.0008 
Needs assistance with daily activities 0.0001 0.0005 
Cancer 0.0000 0.0005 
Nephrology care 0.0000 0.0000 
Chronic obstructive pulmonary disease 0.0000 0.0014 
Age at dialysis initiation 0.0000 0.0016 








Table S1B. Variable importance (VIMP) of 22 potential predictors for arteriovenous fistula 
(AVF) maturation and competing events from Random Survival Forests (RSF) analysis of 1,000 






Potential predictors AVF maturation Competing events 
Gender 0.0040 -0.0002 
Race 0.0016 0.0039 
Body mass index 0.0012 0.0010 
Region 0.0012 0.0021 
Being institutionalized 0.0011 0.0032 
Glomerular filtration rate 0.0011 0.0029 
Network 0.0010 0.0017 
Primary cause of renal failure 0.0009 0.0008 
Days on dialysis without an AVF 0.0009 0.0018 
Congestive heart failure 0.0008 0.0015 
Facility profit status 0.0007 0.0000 
Myocardial infarction 0.0007 0.0033 
Diabetes 0.0007 0.0006 
Atherosclerosis 0.0006 0.0009 
Dyslipidemia 0.0004 -0.0006 
Inability to ambulate 0.0004 0.0007 
Needs assistance with daily activities 0.0003 0.0004 
Serum albumin 0.0003 -0.0002 
Facility hospital association 0.0003 0.0001 
Depression 0.0003 0.0002 
Dementia 0.0002 0.0000 







Table S2. Summary output from Random Survival Forests (RSF) analysis based on 27 and 22 













Total number of variables 27 22 
Sample size 9,829 9,829 
Number of events 4,882 and 1,340 4,882 and 1,340 
Number of trees 1,000 1,000 
Number of variables tried at each split 6 6 
OOB error rate for AVF maturation 45.2% 44.3% 







Table S3. Summary output from Random Survival Forests (RSF) analysis based on 34 potential 






 Training Validation 
Sample size 6,798 3,436 
Number of events 3,411 and 908 1,806 and 386 
Number of trees 1,000 1,000 
Number of variables tried at each split 6 6 
Total number of variables 34 34 
OOB error rate for AVF maturation 45.2% 45.4% 









Table S4. Variable importance (VIMP) of 34 potential predictors for arteriovenous fistula (AVF) 
maturation and competing events from Random Survival Forests (RSF) analysis of 1,000 trees 




Potential predictors AVF maturation Competing events 
Gender 0.0022 -0.0001 
Race 0.0009 0.0037 
Facility profit status 0.0008 0.0000 
Body mass index 0.0008 0.0001 
Myocardial infarction 0.0006 0.0016 
Glomerular filtration rate 0.0006 0.0017 
Days on dialysis without an AVF 0.0006 0.0003 
Serum albumin 0.0005 -0.0003 
Diabetes 0.0005 0.0002 
Age at dialysis initiation 0.0005 0.0010 
Region 0.0004 0.0009 
Being institutionalized 0.0003 0.0025 
Congestive heart failure 0.0002 0.0011 
Facility hospital association 0.0002 -0.0001 
Network 0.0002 0.0006 
Inability to ambulate 0.0002 0.0012 
Dyslipidemia 0.0001 -0.0006 
Needs assistance with daily activities 0.0001 0.0001 
Cerebrovascular disease 0.0001 0.0000 
Amputation 0.0001 0.0000 
Dementia 0.0001 -0.0001 
Chronic obstructive pulmonary disease 0.0000 0.0006 
Inability to transfer 0.0000 0.0001 
Depression 0.0000 0.0002 
Cancer 0.0000 0.0006 
Stroke 0.0000 0.0000 
Peripheral vascular disease 0.0000 -0.0004 
Hypertension 0.0000 0.0000 
Smoke 0.0000 0.0002 
Coronary revascularization 0.0000 -0.0001 
Primary cause of renal failure -0.0001 0.0006 
Atherosclerosis -0.0001 0.0002 
Nephrology care -0.0001 0.0003 
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The principle findings of our studies in older hemodialysis patients could be summarized 
as: (1) only a small proportion of patients have completed the sequential stages from initial AVF 
placement to achieving the goal of AVF patency; and (2) increasing age is significantly 
associated with lower probability of AVF placement and maturation. Although our studies 
indicated the chance of AVF maturation should be the most important consideration for vascular 
access planning, we are not able to establish a clinically friendly model to predict AVF 
maturation for older patients on dialysis. Results of our studies have important implications for 





PART ONE: INDIVIDUALIZED VASCULAR ACCESS STRATEGY  
 
As arteriovenous fistula (AVF) continues to be the favorable vascular access for most of 
hemodialysis patients, there is an increasing call for individualized vascular access strategies for 
dialysis patients.
1-3
 The new 2018 KDOQI Vascular Access Practice Guidelines moves away 




“Fistula First” or “Graft First” Based on Age 
Our study demonstrates “Fistula First” is not the best vascular access strategy for every 
older adult undergoing hemodialysis. The proper candidates should be those who have a strong 
possibility of achieving a matured AVF. More importantly, they should have a reasonable life 
expectancy to reap the post-maturation benefits of an AVF. Thus, “Fistula First” strategy may 
not be superior to “Graft First” in very old hemodialysis patients, e.g. octogenarians and 
nonagenarians. Firstly, as shown by our study, increasing age is significantly associated with 
decreased chance of AVF maturation. Secondly, when placing an AVF in a very old 
hemodialysis patient with a limited life expectancy, we need to justify the short-time benefits 
brought by AVF against the potential harm caused by CVC use while waiting. Nationally, the 
average life expectancy for patients on dialysis aged 80 to 84, and 85 years and older were 2.7 
and 2.2 years, respectively.
5
 Our study shows the median waiting time for AVF maturation is 
approximately 5 months. AVF use for a short period of time may not worth the risk of dialyzing 
with a CVC to get an AVF matured. Nevertheless, arteriovenous graft (AVG) takes much less 
time and efforts to reach successful use (~ 2 to 4 weeks) as compared to AVF. For patients with 
short life expectancy and high probability of AVF failure, AVG may be a better choice. On the 
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other hand, our study supports placing AVF as the initial vascular access in patients 67 to 76 
years old. The likelihood of AVF maturation is similar in patients from 67 to 76 years old and 
higher than those aged 77 and older. Placing AVF in patients of this population may bring long-
term benefits since older adults aged 70 to 74 and 75-79 on hemodialysis may expect to live up 
to 3.8 and 3.3 years on average.
5
 If life expectancy estimated based on an individual’s frailty, 
clinical situation, and comorbid condition is more than 2 years, AVF placement, especially for 
those with a great chance of AVF maturation, might bring overall benefits. 
 
Fistula Interventions and Revisions 
Our study demonstrates a substantial portion of AVF maturation was facilitated by 
endovascular or surgical interventions and AVF patency was maintained by frequent revisions. 
Again, these procedures could be brought as one of the consequences of improper selection of 
AVF candidates encouraged by financial incentives provided by “Fistula First”. Requirement for 
these procedures frequently prolongs CVC dependence. In addition, patient quality of life suffers 
from repeated procedures, which are time-consuming, painful and disruptive to their dialysis 
therapy. These procedures also translate into greater costs for vascular access management. The 
clinician must consider the option of AVG placement in some patients, who have poor venous or 
arterial anatomy, to minimize the need for assisted AVF interventions.  
 
Fistula Maturation Prediction 
There is an urgent need of knowledge to identify patients with a higher chance of AVF 
maturation.  However, our study shows the decrease in predicted accuracy of Lok’s risk equation 
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for primary failure is of such a degree that the model appears useless for clinical decision-
making of vascular access choice in older dialysis patients. In addition, variables captured in the 
USRDS data have limited ability to predict AVF maturation.  As indicated by a recent 
publication from the Hemodialysis Fistula Maturation (HFM) Study, which is a prospective, 
multicenter cohort study examining the association of ultrasound parameters with AVF 
maturation, three post-operative ultrasound parameters exhibit strong predictive ability for AVF 
maturation. A prediction model including AVF blood flow, diameter, and depth achieved good 





ultrasound parameters are included in the prediction model, patient’s case-mix factors (age, 
gender, race, dialysis status, diabetes, BMI and AVF location) are not associated with unassisted 
or overall AVF maturation. This study indicates ultrasound parameters after AVF placement 
have great potential to predict AVF maturation. We highly recommend future studies further 
evaluate these parameters for possibilities to include ultrasound evaluation as a routine clinical 
practice. 
 
PART TWO: PRACTICE PATTERNS IMPROVEMENT 
 
Early Placement of Arteriovenous Fistula 
 
To effectively decrease CVC use, future efforts could be directed at minimizing time 
between the start of dialysis and AVF placement or having AVF placed before dialysis. Our 
study shows, nationally, the median time for AVF placement among older patients who initiated 
dialysis with a CVC is 2 months after dialysis initiation. This is far from reaching the standard of 
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placing an AVF 6 months prior to dialysis proposed by the 2006 and 2018 KDOQI clinical 
guidelines. 
4,7
 If AVFs could be placed early, more time are available for AVF to develop, be 
intervened, and mature so that central venous catheter (CVC) use is avoided.  
However, current reimbursement policy does not have any financial incentives to 
promote predialysis care and there is inadequate reimbursement to encourage surgeons for AVF 
placement.
8
 Timely placement of AVF needs both system and provider level efforts, for example, 
having a defined care pathway that includes patient education, higher eGFR thresholds for 
surgical referral and AVF placement, and a patient tracking database. 
 
Disparities in Fistula Care 
  
Although “Fistula First” has been publicized for more than 15 years, our study 
demonstrates moderate geographic disparities in vascular access care. Especially, the rates of 
AVF placement and patency loss are not uniformly distributed throughout the country. This 
reflects difference in patterns of practice in dialysis facilities. Even under the same “Fistula First” 
policy, some facilities are highly motivated to construct AVFs, while others leave more patients 
dialyzing with a CVC. Some facilities revise AVFs more frequently than others to maintain 
dialysis delivery. Some discard AVFs more frequently than others and replace them with new 
vascular access. We suggest that attention should be especially paid to facilities who had low 
AVF placement rate and yet high rates of primary and secondary patency loss. In these facilities, 
patients wait longer to get an AVF placed. Higher rates of patency loss also indicate improper 
candidates for AVFs, i.e., those with “borderline” vascular features, were selected for AVF 




PART THREE: SUMMARY 
 
Clinical Medicine Implications 
In summary, we recommend clinical practice uses the combination of the estimated 
probability of AVF maturation and life expectancy as the standard to select candidates for AVF 
placement in older hemodialysis patients. For octogenarians and nonagenarians, AVG should be 
placed as the primary vascular access to avoid prolonged CVC use at the beginning of dialysis. 
We also recommend exploring the feasibility of using ultrasound evaluation as a routine clinical 
practice to predict AVF maturation in future studies. Accurately predicting the likelihood of 
AVF maturation will help reduce the medical and economical burdens of AVF interventions and 
revisions. 
 
Public Health Implications 
We suggest Centers for Medicare and Medicaid Services (CMS) adjusts current financial 
policy to encourage early AVF placement in proper candidates or even consider extend financial 
coverage for pre-dialysis vascular access care among older hemodialysis patients so CVC use 
could be reduced or avoided. In addition, they may consider incorporating AVF/AVG patency as 
one of the care index into clinical performance measures (CPM) to establish a comprehensive 
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PART I. Sample SAS Codes for Restricted Cubic Splines (RCS) 
ods graphics on; 






ods rtf close; 





PART II. Sample SAS Codes for Subdistribution Proportional Hazards Regression 
*Subdistribution hazard ratio (SHR) for AVF placement; 
*Age as 2 categories; 
proc phreg data=my.cohort1c1; 
        class age_2cat/descending; 
        model time_place*status_place1(0)=age_2cat/eventcode=1 rl; 
run; 
 
proc phreg data=my.cohort1c1; 
        class age_2cat sex_cat race_cat diabetes hyper stroke mi revas chf cva cancer func nephnew 
region/descending; 
        model time_place*status_place1(0)=age_2cat sex_cat race_cat diabetes hyper stroke mi 
revas chf cva cancer func nephnew region cci bmi album gfr_mdrd/eventcode=1 rl; 
run; 
 
*Subdistribution hazard ratio (SHR) for death; 
proc phreg data=my.cohort1c1; 
        class age_2cat/descending; 
        model time_place*status_place1(0)=age_2cat/eventcode=2 rl; 
run; 
 
proc phreg data=my.cohort1c1; 
  class age_2cat sex_cat race_cat diabetes hyper stroke mi revas chf cva cancer func  
nephnew region/descending; 
        model time_place*status_place1(0)=age_2cat sex_cat race_cat diabetes hyper stroke mi 







PART III. Sample SAS Codes for Crude and Inverse Probability Weighted Cumulative 
Incidence Function (CIF) 
 
*Set graph options; 
goptions device=png targetdevice=png gsfname=grafout gsfmode=replace xpixels=1500 
ypixels=1200; 
axis1 label=(height=2 "Days") value=(font="Times" height=2) order=(0 365 730 1095); 
axis2 label=(angle=90 height=2 "AVF Placement (Bottom)") order=(0.0 0.2 0.4 0.6 0.8 1.0) 
value=(font="Times" height=2); 
axis3 label=(angle=90 height=2 "Competing Events (Top)") order=(1.0 0.8 0.6 0.4 0.2 0.0) 
value=(font="Times" height=2); 
 
legend1 across=1 position=(bottom right inside) noframe label=none shape=line(5) 
value=(justify=left font="Times" 
height=2.5 "67-<77" "77+"); 
symbol1 c=black l=1 w=3 v=none i=stepjs; 
symbol2 c=black l=3 w=3 v=none i=stepjs; 
symbol3 c=black l=1 w=3 v=none i=stepjs; 
symbol4 c=black l=3 w=3 v=none i=stepjs; 
 
ods rtf file='CIF AVF placement crude.rtf'; 
proc gplot data=cif_cd; 
        plot cif1*time_place=age_2cat/nolegend haxis=axis1 vaxis=axis2; 
 plot2 cif2*time_place=age_2cat/vaxis=axis3 legend=legend1; 
        title1 font="Times" height=2.5 "Crude Cumulative Incidence Function (CIF)"; 
run; 
 





proc logistic descending data=my.cohort1c1 noprint; 
        model age_2cat=; 
        output out=o1 prob=tn; 
run; 
proc logistic descending data=my.cohort1c1 noprint; 
 class sex_cat race_cat diabetes hyper stroke mi revas chf cva cancer func nephnew 
region; 
        model age_2cat=sex_cat race_cat diabetes hyper stroke mi revas chf cva cancer func 
nephnew region cci bmi album gfr_mdrd; 
        output out=o2 prob=td; 
run; 
proc sort data=o1;by usrds_id;run; 




        merge o1 o2; 
        by usrds_id; 
run; 
data b(drop=_level_ tn td); 
        set o12; 
        by usrds_id; 
        if age_2cat='0' then do;tn=1-tn;td=1-td;end; 
        tw=1/td; 
        stw=tn/td; 
run; 
 
*Weighted CIF in competing risk analysis; 
proc lifetest data=b outcif=cif3; 
        time time_place*status_place1(0)/eventcode=1; 
        freq stw/notruncate; 
 strata age_2cat; 
run; 
 
proc lifetest data=b outcif=cif4; 
        time time_place*status_place1(0)/eventcode=2; 
        freq stw/notruncate; 
 strata age_2cat; 
run; 
 
proc sort data=cif3;by age_2cat time_place;run; 
proc sort data=cif4;by age_2cat time_place;run; 
 
data cif_wt; 
        merge cif3(in=x rename=(cif=cif3)) cif4(in=y rename=(cif=cif4)); 
        by age_2cat time_place; 
        if x and y; 
run; 
 
*Set graph options; 
goptions device=png targetdevice=png gsfname=grafout gsfmode=replace xpixels=1500 
ypixels=1200; 
axis1 label=(height=2 "Days") value=(font="Times" height=2) order=(0 365 730 1095); 
axis2 label=(angle=90 height=2 "AVF Placement (Bottom)") order=(0.0 0.2 0.4 0.6 0.8 1.0) 
value=(font="Times" height=2); 
axis3 label=(angle=90 height=2 "Competing Events (Top)") order=(1.0 0.8 0.6 0.4 0.2 0.0) 
value=(font="Times" height=2); 
 
legend1 across=1 position=(bottom right inside) noframe label=none shape=line(5) 
value=(justify=left font="Times" 
height=2.5 "67-<77" "77+"); 
symbol1 c=black l=1 w=3 v=none i=stepjs; 
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symbol2 c=black l=3 w=3 v=none i=stepjs; 
symbol3 c=black l=1 w=3 v=none i=stepjs; 
symbol4 c=black l=3 w=3 v=none i=stepjs; 
 
 
ods rtf file='CIF AVF placement weighted.rtf'; 
proc gplot data=cif_wt; 
        plot cif3*time_place=age_2cat/nolegend haxis=axis1 vaxis=axis2; 
        plot2 cif4*time_place=age_2cat/vaxis=axis3 legend=legend1; 
        title1 font="Times" height=2.5 "Weighted Cumulative Incidence Function (CIF)"; 
run; 




PART IV. Sample SAS Codes for Testing Proportional Hazards Assumption; 
 
%let GraphOpts=attrpriority=none DataContrastColors=(black) DataColors=(black); 
 
ods rtf file='proportional check_place.rtf'; 
 
*Cause-specific; 
*Log of negative log of survival vs. log of time; 
proc lifetest data=my.cohort1c1 plot(only)=(lls) noprint; 
        time time_place*status_place1(0,2); 
        strata age_2cat; 
 label time_place='Months'; 
run; 
ods rtf close; 
 
*time-age interaction; 
proc phreg data=my.cohort1c1; 
        class age_2cat/descending; 






proc phreg data=my.cohort1c1; 
        class age_2cat/descending; 







PART V. SAS Codes for C Statistics; 
 
ods graphics on; 
ods rtf file='Figure 2.C statistics_black&white.rtf' style=journal; 
proc logistic data=my.cohortnew2; 
        model status_failure(event="1")=; 
        roc pred=prob_failure; 
roccontrast; 
run; 
ods rtf close; 
ods graphics off; 
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PART VI. SAS Codes for Calibration Plot; 
 
ods graphics on; 
ods rtf file='Figure 3. Calibration plot_black&white.rtf' style=journal; 
proc sgplot data=cali noautolegend aspect=1; 
        lineparm x=0 y=0 slope=1/lineattrs=(color=gray pattern=dash); 
        loess x=prob_failure y=prob_obs; 
        scatter x=prob_failure y=prob_obs; 
        yaxis label='Observed Probability of Fistula Failure' values=(0 to 0.7 by 0.1); 
        xaxis label='Predicted Probability of Fistula Failure' values=(0 to 0.7 by 0.1); 
 
run; 





PART VII. SAS Codes for Training and Validation Data Sets 
 
*randomly divide the cohort to training (2/3) and validation (1/3) subcohorts; 
proc surveyselect data=cohort samprate=0.66 seed=12345 out=cohort_select outall 




proc freq data=cohort_select;tables selected/list;run; 
data one (drop=selected) two(drop=selected); 
set cohort_select; 
if selected=1 then output one; 



























##Build a forest 
##bootstrap is default, by.root 
##importance is default, importance=TRUE, computationally expensive 
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